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THE STRUCTURAL MECHANISM OF ALLOSTERIC
MODULATION OF THE NMDA RECEPTOR:
A BALANCE OF TENSIONS
Abstract

Rita Evelyn Sirrieh, B.S.

Advisory Professor: Vasanthi Jayaraman, Ph.D.

N-methyl-D-aspartate (NMDA) receptors are one of the three main types of ionotropic
glutamate receptors in the central nervous system. NMDA receptors mediate the rapid
excitatory neurotransmission that underlies learning and memory formation. Conversely,
NMDA receptors are implicated in a variety of neurological disorders. Studies targeting the
mechanism of allosteric modulation, such as this study, hope to contribute to the
understanding of how NMDA receptors are modulated to allow for better drug development.
NMDA receptors are obligate heterotetramers, typically composed of glycine-binding
GluN1 subunits and glutamate-binding GluN2 subunits. The GluN2 subunits can be one of
four subtypes (A-D). Each subunit is organized into distinct domains: extracellular aminoterminal (ATD) and ligand-binding domains, the transmembrane, pore-forming domain, and
an intracellular carboxyl-terminal domain. The ATD includes the binding site of a number of
allosteric modulators. Endogenous modulators such as the zinc cation or spermine can inhibit
and potentiate current through the receptor, respectively. The synthetic compound ifenprodil
also binds the ATDs and inhibits the receptor. We used luminescence resonance energy
transfer to study the structural changes accompanying modulator binding and then linked
those conformational changes to the function of the receptor using electrophysiology. LRET

vi

measurements were made between subunits to determine the architecture of the ATDs in an
assembled receptor.
Our studies reveal that the ATDs have a compact overall organization, and that the
inherent conformation of a GluN1 or GluN2 ATD varies in a fashion that correlates with the
open channel probability of the receptor. Additionally, modulator binding to the ATDs induces
conformational changes. Inhibitors, such as zinc and ifenprodil, induce a closure in the GluN2
ATD, whereas the potentiator spermine induces an opening of the GluN2 ATD. The lower
lobes of the ATDs undergo a rotational movement when any allosteric modulator was bound,
suggesting the rotation of the domain is independent of the open/close mechanism. These
studies reveal that the receptor can be modulated by influencing the conformation of the ATD.
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Chapter 1:
Introduction to Glutamate Receptors

1

1.1 Introduction to Synaptic Transmission and iGluRs
Glutamate is the primary excitatory neurotransmitter in the central nervous system.
Glutamatergic signaling is responsible for processes which underlie learning and memory
formation through long-term potentiation and long-term depression. When an action potential
reaches the pre-synaptic nerve terminal, membrane depolarization followed by a calcium
influx into the presynaptic nerve terminal triggers the release of synaptic vesicles containing
glutamate. The released glutamate travels across the synaptic cleft and binds to one of three
glutamate receptors on the post-synaptic nerve terminal. The glutamate signal is then cleared
away, partly by the diffusion of glutamate out of the synapse, but mostly by the action of
glutamate transporters which recycle glutamate to be re-packaged into synaptic vesicles.
Glutamatergic signaling results in rearrangements of the synapse resulting in a long-term
change in the mechanism of synaptic signaling. The focus of this dissertation is on the
glutamate receptors that receive the signal on the post-synaptic nerve terminal.

Ionotropic Glutamate Receptors (iGluRs)

AMPA Receptors
GluA1-4

Kainate Receptors
GluK1-4

NMDA Receptors
GluN1, GluN2A-D,
GluN3A-B

Figure 1.1: Schematic of iGluR subtypes. iGluRs can be
subdivided into three classes: AMPA, kainate, and NMDA receptors.
Ionotropic glutamate receptors (iGluRs) can be subdivided into three subtypes, which
are named for the synthetic agonist that can activate the channel to the same extent as
glutamate, a full agonist: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), Nmethyl-D-aspartate (NMDA), and kainate receptors (Figure 1.1). iGluRs were first cloned in
early 1989, followed by a flurry of additional clones in the early 1990s (Hollmann, O'Shea2

Greenfield et al. 1989, Bettler, Boulter et al. 1990, Boulter, Hollmann et al. 1990, Egebjerg,
Bettler et al. 1991, Moriyoshi, Masu et al. 1991, Werner, Voigt et al. 1991, Sugihara, Moriyoshi
et al. 1992), and their discovery spurred decades of intense research. The receptors are
named for the synthetic agonists which activate the channel to the same extent as the
physiological full agonist, glutamate. Kainate receptors play roles on both the pre- and postsynaptic terminals and are more involved on the postsynaptic side early in development. In
adults, AMPA and NMDA receptors are the primary post-synaptic receptors. Glutamate
released from the pre-synaptic terminal binds to both the AMPA and NMDA receptors. At
resting membrane potentials, however, NMDA receptors are pore-blocked by the Mg2+ cation
(Mayer, Westbrook et al. 1984, Nowak, Bregestovski et al. 1984). AMPA receptor activation
results in a sodium influx into the post-synaptic neuron, which induces membrane
depolarization, and relieves the magnesium block of the NMDA receptor. For this reason,
NMDA receptors are called coincidence detectors; they detect a coincident electrical
(membrane depolarization) and chemical (glutamate) signal. NMDA receptors require two
ligands to activate the receptor, glycine or D-serine in addition to glutamate. Glycine or Dserine are always present in the synaptic cleft, and a recent study suggests that the type of
agonist present depends on the brain region and stage of development (Le Bail, Martineau et
al. 2014). These activated NMDA receptors are sodium and calcium permeable and further
depolarize the post-synaptic neuron. Moreover, calcium entering the post-synaptic neuron
activates many downstream processes, which during learning and memory formation and
consolidation result in growth and rearrangement of the synapse.

1.2 Overall Architecture of iGluRs
iGluRs share a common overall assembly in that they are tetrameric in nature and
organized into distinct domains (Figure 1.2). AMPA and kainate receptors can form as

3

Figure 1.2: Full-length structures of iGluRs. (A) The crystal structure of the GluA2 AMPA
receptor bound to the antagonist ZK 200775 (PDB ID 3KG2) was the first full iGluR structure
solved (Sobolevsky, Rosconi et al. 2009, Tomitori, Suganami et al. 2012). The four subunits
of the AMPA receptor are assigned a letter to make it easier to refer to the subunit: A-red,
B-gold, C-green, D-blue. (B) The cryo-EM structure of the GluK2 kainate receptor (PDB ID
4UQQ) was solved bound to 2S,4R-4-methylglutamate (Meyerson, Kumar et al. 2014). (C)
The crystal structure of the heteromeric GluN1-GluN2B NMDA receptor (PDB ID 4PE5)
bound to glutamate, glycine, and ifenprodil is shown with the GluN1 subunits in green and
red and the GluN2B subunits in gold and blue. Each of the structures lacks the intracellular
carboxyl-terminal domain.
homomeric or heteromeric species, whereas the NMDA receptor is an obligate heteromer.
Each of the four subunits in the AMPA receptor is, by convention, assigned a letter (A-D) to
facilitate talking about specific subunits and interactions. In Figure 1.2 the subunits are shown
in different colors: A-red, B-gold, C-green, D-blue. The receptor assembles as a pair of dimers
that has four-fold symmetry at the pore, but only a two-fold symmetry at the LBDs, so that
there is asymmetry among the LBDs despite the structure being of a homomer. At the LBDs,
the pairs of domains are of the B/C and A/D subunits. Before the structure of the NMDA
receptor was available, fluorescence studies and cross-linking followed by western blots were
used to determine the arrangement of subunits (Rambhadran, Gonzalez et al. 2010,
Salussolia, Prodromou et al. 2011, Riou, Stroebel et al. 2012, Sirrieh, MacLean et al. 2013).
These studies all showed that the NMDA receptor subunits assemble in an alternating fashion,
4

also called a dimer of heterodimers. The GluN1 subunits were found to correspond to the A/C
positions on the AMPA receptor, while GluN2 subunits correspond to B/D positions at the
LBDs. Additionally, the cross-over between the ATD and LBD layer was predicted to be
maintained in NMDA receptors. At the ATD layer, the dimers are of the A/B and C/D subunits
due to the crossover. When the receptor is viewed from the side, it appears in layers due to
the association of the distinct domains with each other (Figure 1.2). The assembly of subunits
is quite similar between AMPA and kainate receptors; the receptor has an overall ‘Y’ shape.
NMDA receptors have a more compact arrangement between the extracellular domains
(Figure 1.2 and 1.2).
Recently, the full-length structure of the NMDA receptor was solved by two labs (Karakas
and Furukawa 2014, Lee, Lü et al. 2014). These structures, though lacking the CTDs, are the
most complete structures to date of the NMDA receptor. One structure is bound by ifenprodil,
glutamate, and glycine (shown in Figure 1.2) (Karakas and Furukawa 2014). The second
structure is bound by Ro25-6981, ACPC, t-ACBD, and the open-channel blocker MK-801
(Lee, Lü et al. 2014). These structures reveal that, like the kainate and AMPA receptors
(Sobolevsky, Rosconi et al. 2009, Meyerson, Kumar et al. 2014), the LBDs and ATDs are
organized as a dimer of heterodimers. Further, there is a crossover between the LBD and
ATD layers, where the ATD of a subunit sits atop the LBD of the adjacent subunit (Figure 1.2
and 1.3). This crossover is especially clear if panels B and C of Figure 1.3 are compared; the
ATD of a subunit does not sit directly above the LBD contributing to the LBD dimer pair.
Likewise, the LBD of a subunit does not sit directly below the ATD contributing to the ATD
dimer pair (Figure 1.3).
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Figure 1.3: Crystal structures of the full-length NMDA receptor. (A)
The heterotetrameric crystal structure of the GluN1/GluN2B NMDA
receptor in complex with the agonists glutamate and glycine and the
allosteric inhibitor ifenprodil (PDB ID 4PE5). The structure in the right half
of panel A shows the structure 90°. (B) The full structure of a dimer
highlighting the dimer pair at the LBD layer is shown. (C) The full subunit
structure of a dimer highlighting the dimer pair at the ATD layer is shown.
Each subunit of the NMDA receptor is structurally organized into distinct domains: an
extracellular amino terminal domain (ATD) and ligand-binding domain (LBD), the pore-forming
transmembrane domain (TMD), and an intracellular carboxyl-terminal domain (CTD) (Figure
6

1.3). The upper lobe and lower lobes of the LBD are called S1 and S2, respectively. The
topology of the protein is such that the extracellular N-terminus begins with the amino terminal
domain, connects to S1 of the LBD, then inserts into the membrane to form the M1, M2, and
M3 helices, then forms the S2 of the LBD, which finally connects to M4 and then the
intracellular CTD. As such, the LBD is connected to the TMD via three linkers, called the S1M1 linker, M3-S2 linker, and S2-M4 linker. Each domain of the NMDA receptor has a distinct
function. The ATD and LBD are structurally distinct enough that an individual domain can be
expressed as soluble protein, and the first crystal structures of iGluRs were of isolated
domains (Armstrong and Gouaux 2000, Furukawa and Gouaux 2003, Furukawa, Singh et al.
2005).

1.3 Subtypes and Splice Variants of Glutamate Receptors
The NMDA receptor can be composed of three different types of subunits: GluN1,
GluN2, and GluN3. GluN1 subunits bind glycine or D-serine as the agonist and can be one of
eight different splice variants (GluN1-1 to GluN1-4 and each can be either a or b). The GluN1
splice variant is designated ‘a’ if it does not include exon 5 or ‘b’ if it does. The ‘a’ splice variant
is more common than the ‘b’ splice variant (Paoletti 2011). The other two exons that can be
differentially spliced are in the intracellular C-terminus. GluN2 subunits bind glutamate as the
agonist and can be one of four subtypes arising from four different genes, designated A-D.
GluN3 subunits also bind glycine or D-serine as the agonist and can be one of two subtypes,
A or B. Functional NMDA receptors are composed of at least two different subunits, most
commonly GluN1 and GluN2. The different splice variants and subtypes are expressed
variably throughout the central nervous system, and the subunit composition in various brain
regions changes during development. During fetal development GluN2B is the primary GluN2
subtype until a switch takes place a few weeks after birth and GluN2A becomes the most
common subtype (Paoletti 2011). GluN2C subunits are expressed late in embryonic
7

development and in the adult brain are mostly found in the cerebellum (Paoletti 2011). Finally,
the GluN2D subunit is always poorly expressed and in adults is found only in the diencephalon
and brainstem (Paoletti 2011). The subunit composition dictates the gating kinetics of the
receptor and the affinity for agonists, antagonists, and modulators. As a result, the variability
in NMDA receptor subunit composition defines the shape of synaptic signaling in a particular
brain region.
The different subtypes of the NMDA receptor share varying degrees of sequence
homology. Across all four GluN2 subtypes, there is an overall 25% sequence identity. This
identity varies depending on the domain of the receptor being compared. The TMDs have the
highest sequence identity (73%), with higher sequence identity if comparing certain pairs of
subunits. The LBDs have a sequence homology of 63%, while the ATDs have only 19%
sequence homology. The CTDs have the least sequence homology, only 2% across all GluN2
subtypes. The GluN1 and GluN3 subunits, despite both being glycine binding subunits, have
relatively low sequence homology across all domains, up to 19%, with an overall sequence
homology of 5% across all splice variants and subunits. These values were all reviewed in
S.F. Traynelis, et al., 2010 (Traynelis, Wollmuth et al. 2010).
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1.4 Functions of ATDs and binding sites of modulators
The ATDs of the NMDA receptor are the most extracellular part of the receptor (most
distal to the membrane) and are about 350-400 amino acids in length. The domain is
organized in two lobes that form a clam-shell like structure, similar to the bacterial leucineisoleucine-valine binding proteins (LIVBPs) to which they are structurally homologous. The
ATDs are involved in receptor assembly (Meddows, Bourdellès et al. 2001) and dictate the
open probability (Po) of the channel (Gielen, Retchless et al. 2009, Yuan, Hansen et al. 2009).
Additionally, the GluN2 ATD determines agonist potency (Yuan, Hansen et al. 2009). Most
importantly, the ATDs contain the binding sites for allosteric modulators of receptor function.
Endogenous and exogenous modulators of the receptor have been identified that bind to the
ATDs (Figure 1.4 for binding sites). The zinc cation is an endogenous inhibitor of the receptor
that binds within the bi-lobed cleft of the GluN2 ATD. Spermine, an endogenous potentiator,

Figure 1.4: Modulator Binding Sites. The GluN1-GluN2B
ATD dimer is shown with GluN1 in teal and GluN2B in
orange. Highlighted in red are the acidic residues involved in
spermine binding. In pink is ifenprodil in its binding site. The
blue residues in GluN2B are His128 and Asp284, which
coordinate the zinc cation. In GluN2A, His42 and His44 help
these residues to coordinate zinc.
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is thought to bind between the GluN1 and GluN2 ATDs, but only potentiates GluN2B
containing receptors. Synthetic compounds called phenylethanolamines similarly bind
between the GluN1 and GluN2B ATDs and inhibit current from the receptor. Two compounds
from this class, ifenprodil and Ro25-6981 were found to bind to the same binding site between
the two ATDs (Karakas, Simorowski et al. 2011).
A linker connects the ATD to the LBD (called the ATD-LBD linker). This linker is
important to the modulation of Po by the ATD. Chimeras that swap just the ATD-LBD linker
between GluN2A and GluN2D subunits, can alter the Po of the receptor to match that which

Figure 1.5: iGluR ATDs. The ATD dimers from AMPA (A), kainate (B), and NMDA (C)
receptors are shown. The NMDA ATD dimer is of the GluN1-GluN2B ATDs (GluN1-green,
GluN2B-blue). It is clear from looking at these structures that the ATDs of NMDA receptors
adopt unique conformations. The upper lobes make extensive contacts, but the lower lobes
are uninhibited by contacts and free to move.
contributed the linker (Gielen, Retchless et al. 2009, Yuan, Hansen et al. 2009). The linkers
are about ~15 residues long, and about 1/3 of the residues are conserved between the
GluN2A and GluN2D subtypes.
The structures of AMPA and kainate receptor ATDs are quite similar (Figure 1.5). The
structures of individual ATDs align to each other with an RMSD of 2.116 Å, while homomeric
ATD dimers align with an RMSD of 2.431 Å. These structures align fairly well to the GluN1
ATD, but the GluN2B ATD in the dimer seems rotated. When the GluN2B ATD structure was
initially solved, the authors noted how the lower lobe of the GluN2B ATD was rotated by about
10

45° and 54° compared to the ATDs of AMPA and kainate receptors, respectively (Karakas,
Simorowski et al. 2009). The difference in the structure of the GluN2B ATD was suggested as
a critical component to the ability of NMDA receptors to bind allosteric modulators at the ATDs.
AMPA and kainate receptor ATDs have extensive contacts along the whole of the ATDs.
However, the contacts between GluN1 and GluN2 ATD are contained solely at the upper
lobes, such that the lower lobes of the ATDs are free to move or interact with other domains
as needed or spurred to by a modulator (Karakas, Simorowski et al. 2009, Stroebel, Carvalho
et al. 2011).

1.5 LBDs and gating
The LBDs are about 250-300 amino acids in length and also form a clamshell which
contains the binding sites for the agonists. In the AMPA receptor, the agonist first interacts
with the upper lobe of the LBD, and subsequent contacts with the lower lobe of the LBD cause
the domain to close around the agonist. This domain closure around the agonist has been
confirmed by crystal structures, functional studies, and LRET studies of the isolated LBDs
(Armstrong and Gouaux 2000, Furukawa and Gouaux 2003, Furukawa, Singh et al. 2005,
Gonzalez, Rambhadran et al. 2008, Rambhadran, Gonzalez et al. 2011). Further, single
molecule studies reveal the dynamics involved and the spread of states explored by the LBDs;
LBDs tend to explore a greater degree of conformations in the apo or antagonist bound states,
but lesser conformations (i.e. a more narrow distribution of states) with increasing efficacy of
the agonist (Landes, Rambhadran et al. 2011, Ramaswamy, Cooper et al. 2012, Dolino,
Cooper et al. 2014). The extent that the domain closes around the ligand can be directly
correlated to the extent of activation of the receptor.
Much work has focused on understanding the structural mechanism of iGluR gating.
Studies in AMPA receptors showed that when the agonist binds to the LBD and the domain
closes around the agonist, the interface between subunits, aptly named the dimer interface,
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forms new contacts that stabilize the state (Figure 1.6). The conformational changes at the
LBDs pull on the linkers to the TMD to open the channel. Much early work was done on AMPA
receptors, and in the AMPA receptor, only two subunits need to be bound to agonist for the
channel to activate, corresponding to the lowest subconductance state (Rosenmund, SternBach et al. 1998). Subsequent binding of a third and fourth agonist to their respective subunit
results in activation of the receptor to two additional subconductance states (Rosenmund,
Stern-Bach et al. 1998). Eventually, the dimer interface contacts rupture, and although the
LBDs remain closed around the agonist, the channel is closed, a state called the desensitized
state. A mutation in the dimer interface of the AMPA receptor, Leu483Tyr, eliminates
desensitization because the tyrosine aromatic rings stack together and stabilize the LBD
dimer interface to where it does not break in the continual presence of agonist (Stern-Bach,
Russo et al. 1998, Robert, Irizarry et al. 2001). The compound cyclothiazide, which binds at
the AMPA receptor dimer interface, similarly prevents the receptor from desensitizing by
stabilizing the dimer interface in the continual presence of agonist (CM 1993, Trussell, Zhang
et al. 1993, Partin, Patneau et al. 1994). The time course for the entry into desensitization is
18-34 msec, and the receptors desensitize almost completely (Indira and Trussell 1992,
Robert, Irizarry et al. 2001). The entry into desensitization depends on the subtype composing
the AMPA receptor and also on whether the receptor is recombinantly expressed or being
recorded in neurons; the neuronal AMPA receptors interact with regulatory proteins that
greatly influence receptor kinetics. AMPA receptors recover from desensitization with a

rec

on

the order of milliseconds, but the actual time constant varies with the subtype forming the
receptor (Raman and Trussell 1995, Robert and Howe 2003). AMPA receptors desensitize
from the closed state, and binding of one glutamate to one subunit is sufficient to desensitize
the receptor (Robert and Howe 2003).
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NMDA receptors activate in a similar fashion to AMPA receptors, but they require two
agonists, glutamate and either glycine or D-serine, because the receptors are obligate
heterotetramers. Unlike the AMPA receptor, all four ligands, two glutamates and two glycines,
need to bind in order for the channel to open. Also, the NMDA receptor desensitizes to a much
lesser degree than the AMPA receptor, and on a much slower time scale (Table 1.1). The role
of the dimer interface in NMDA receptor gating remains poorly understood, and experiments
targeting the dimer interface yield interesting and sometimes conflicting results. Cross-links
that are intended to stabilize the NMDA receptor dimer interface instead result in a reduction
in the peak current elicited in a patch and the receptors still desensitize (Borschel, Murthy et
al. 2011). Additionally, the cross-links across the LBDs result in a decrease in agonist affinity
(Gielen, Le Goff et al. 2008). Further, no mutation or pharmacological agent has been
discovered that completely eliminates desensitization exists as has been found for AMPA
receptors. The kinetics of desensitization when the receptor include the GluN2A subtype also

Figure 1.6: Schematic of iGluR gating. Upon binding of the agonists to the LBDs, the
domain closes around the agonist, the dimer interface forms new contact, and the pore
of the channel is opened. Eventually, the dimer interface ruptures and, although the
agonists are bound and the domain is closed around the agonist, the channel is closed.
13

depend on the extracellular zinc concentrations, as zinc increases the rate of desensitization
(Erreger and Traynelis 2008).
The LBD-TMD linkers play a role in gating because they propagate the conformational
changes induced by agonist binding at the LBD to open the pore of the receptor. Recent work
has demonstrated that inserting a single glycine residue in the M3-S2 linker is enough to
decouple conformational changes at the LBD from the TMD, resulting in an inability to
efficiently open the pore of the receptor (Kazi, Dai et al. 2014). The TMD is composed of three
transmembrane helices (M1, M3, and M4) and a reentrant pore loop (M2). The M3 helices,
one from each subunit, come together to form the pore of the channel. M4 connects to the
intracellular CTD. A residue at the base of the M3 helix of GluN2 subunits has been identified
which confers sensitivity to magnesium pore block and dictates single channel conductance
and calcium permeability (Retchless, Gao et al. 2012). In GluN2A and GluN2B subunits, this
residue is a serine (residue 632 and 633, respectively). GluN2A and GluN2B subunits have
higher affinity for magnesium, higher
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GluN2A

GluN2B

GluN2C

GluN2D

0.61 ± 0.05

0.20 ± 0.03

0.032 ± 0.015

0.012 ± 0.002

Glutamate EC50 (µM)

3.3

1.3

0.8

0.35

Glycine EC50 (µM)

1.1

0.18

0.14

0.23

Deactivation (ms)

40 ± 4, 560 ±
140 (15)

310 ± 30,
1100 ± 190
(40)

110 ± 30, 310
± 35 (50)

2100 ± 150,
5700 ± 510
(53)

MOT (ms)

8.3 ± 0.8

5.1 ± 0.4

0.35 ± 0.07

0.42 ± 0.037

MCT (ms)

5.1 ± 0.7

37 ± 6

24.3 ± 10.6

24 ± 5.6

Rise Time (ms)

7.4 ± 0.7

11.6 ± 1.2

3.9 ± 0.4

4.4 ± 0.59

Rate of Entry into
Desensitization (ms)

59.9, 257

142, 888

59, 720

N.D.

ΔATD Po

0.006 ± 0.003

N.D.

N.D.

0.065 ± 0.015

Zinc IC50

16 nM

760 nM

18 µM

9.2 µM

Popen

Table 1.1: Properties of NMDA receptors. Kinetics of gating and sensitivity to
modulators vary based on the GluN2 subtype. Values were taken from the following
papers: (Erreger, Dravid et al. 2005, Rachline, Perin-Dureau et al. 2005, Erreger and
Traynelis 2008, Gielen, Retchless et al. 2009, Yuan, Hansen et al. 2009, Mullasseril,
Hansen et al. 2010, Talukder and Wollmuth 2011, Amico-Ruvio, Paganelli et al. 2012,
Vance, Hansen et al. 2013, Khatri, Burger et al. 2014). N.D. Not Determined
single channel conductance, and greater calcium permeability. However, in GluN2C and
GluN2D subunits, the residue is a leucine. These receptors have a lower affinity for
magnesium, low single channel conductance, and less calcium permeability (Retchless, Gao
et al. 2012). The serine residue in GluN2A/B interacts with Trp608 in the GluN1 subunit and
effects receptor properties by this interaction rather than by direct interaction with permeating
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ions (Retchless, Gao et al. 2012). Additionally, by using the substituted cysteine accessibility
method, many exposed residues in the TMD were identified, and changes due to binding of
an agonist results in different accessibilities (Talukder, Borker et al. 2010).

1.6 Gating Kinetics
Kinetic studies of iGluR gating reveal that there are several kinetic steps that the receptor
goes through after binding the agonists but prior to activation of the channel. Several kinetic
models have been proposed to explain NMDA receptor gating. Additionally, the activated
NMDA receptor undergoes modal gating: while the channel is open, the channel will vary
between three different ‘modes’ of activation corresponding to different lifetimes of open states
(Popescu and Auerbach 2003). The three modes of activation were identified and named high,
medium, and low. Only transitions between adjacent states (high-medium, medium-low, and
vice versa) were identified. These states have lifetimes on the order of milliseconds and occur
within a burst from an individual channel. Recordings from NMDA receptors in neurons show
that these receptors also undergo modal gating (Zhang, Howe et al. 2008). The physiological
purpose of modal gating is still largely unknown.
Open probability, the chance that the channel is open at any given time, varies based
on the type of GluN2 subunit (Chen, Luo et al. 1999, Erreger, Dravid et al. 2005). Receptors
containing the GluN2A subtype have the highest Po (0.61 ± 0.05), the GluN2B subtype
confers intermediate Po (0.20 ± 0.03), and GluN2C and GluN2D containing receptors have
low Po (0.032 ± 0.015 and 0.012 ± 0.002, respectively) (Table 1.1). Also given in Table 1.1
are various kinetic parameters of the NMDA receptor for each of the GluN2 subtypes. The
desensitization rate of GluN2D receptors has not been quantified because the GluN2D
containing receptors do not desensitize (<10%) [8]. GluN2A and GluN2B containing receptors
have a high main conductance state of ~50 pS, with a subconductance state of ~37 pS [63].
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GluN2C and GluN2D containing receptors have a lower main conductance state of ~37 pS
and a subconductance state of ~18 pS [63].

1.7 Cooperativity between ATD and LBD
As mentioned above, the GluN2 ATD dictates open probability, glutamate EC50,
glycine EC50, and deactivation kinetics (Zheng, Erreger et al. 2001, Erreger and Traynelis
2005, Madry, Mesic et al. 2007, Gielen, Retchless et al. 2009, Yuan, Hansen et al. 2009).
Studies where chimeric receptors were made so that the ATD of GluN2 subunits were
switched to the ATD of other subtypes showed that the kinetics matched those of the subunit
which contributed the ATD. Further, deletion of the ATD alters kinetics. In GluN2A subunits,
the Po is significantly decreased when the ATD is deleted. GluN2B containing receptors,
which have an inherently lower Po, do not have a significantly different Po when the ATD is
deleted. The structural link between the ATD and LBD remains unknown. The recent crystal
structures reveal a quite compact arrangement of the subunits with more extensive direct
contacts between the ATD and LBD layers than previously anticipated based on the structure
of the AMPA receptor, although the constructs used to generate these crystal structures had
several deletions in the ATD-LBD linker which may have artificially increased the interface
between the ATD and LBD layer, as seen recently in the AMPA receptor (Sobolevsky, Rosconi
et al. 2009, Meyerson, Kumar et al. 2014).
Several links have been established between the ATD and LBD. The binding of
allosteric inhibitors zinc or ifenprodil to the ATD increases the receptor’s affinity for the
agonists. In the case of allosteric inhibition, this is especially interesting when the inhibitor is
thought to push the receptor to the desensitized state, because the AMPA receptor has
increased affinity for the agonist in the desensitized state. This similarity suggests that the
inhibitors do indeed push the receptor a desensitized state, at least structurally. However, the
link extends beyond desensitization, because the potentiator spermine also increases the
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affinity for the agonists. Binding of zinc to the ATD of the NMDA receptor results in an increase
in the affinity of the agonists glutamate and glycine. The coooperativity also exists in reverse;
binding of NMDA to the receptor increases the apparent affinity of ifenprodil to the NMDA
receptor (Kew, Trube et al. 1996).

1.8 Functions of the CTD
The CTD of NMDA receptors is rather large, especially as compared to that of other
glutamate receptors, and is thought to be intrinsically disordered (Choi, Kazi et al. 2013). The
CTD is involved in trafficking, synaptic localization, anchoring to the post-synaptic density,
and can modulate receptor function via phosphorylation and protein-protein and protein-lipid
interactions (Traynelis, Wollmuth et al. 2010). Proteins including α-actinin, calmodulin,
CaMKII, and PSD-95 bind to the CTD (Ehlers, Zhang et al. 1996, Merrill, Malik et al. 2007).
The CTDs are phosphorylated by the kinases CaMKII, PKA, PKC, and Src (Maki, Program et
al. 2013, Wang, Guo et al. 2014). Recent studies have shown that post-translational
modifications at the CTD can influence conductance and decay kinetics (Maki, Aman et al.
2012, Maki, Program et al. 2013). Phosphorylation of the CTD can reduce the extent of zinc
inhibition (Zheng, Gingrich et al. 1998). Also, calcium that enters the cell through the activated
NMDA receptor, binds to calmodulin, which binds to the CTD of GluN1 subunits and causes
calcium dependent inactivation of the receptor (Ehlers, Zhang et al. 1996, Zhang, Ehlers et
al. 1998, Ataman, Gakhar et al. 2007, Merrill, Malik et al. 2007). The structural mechanism of
calcium dependent inactivation is still unknown.
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Chapter 2:
Allosteric Modulators of the NMDA Receptor:
Zinc, Ifenprodil, and Spermine
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2.1 Zinc at Synapses
In the central nervous system, the zinc cation is a specific inhibitor of several ion
channels, including the NMDA receptor (Peters, Koh et al. 1987, Westbrook and Mayer 1987),
the GABAA receptor (Ruiz, Walker et al. 2004), and the glycine receptor (Trombley, Blakemore
et al. 2011), and can modulate kainate receptor function (Veran, Kumar et al. 2012). There
was growing evidence at the time of synaptically present and released zinc, something that
has now been firmly established, and the predicted concentrations range from the low nM to
the high µM (Assaf and Chung 1984, Howell, Welch et al. 1984, Aniksztejn, Chraton et al.
1987, Vogt, Mellor et al. 2000, Li, Hough et al. 2001, Molnar and Nadler 2001, Ueno,
Tsukamoto et al. 2002, JL 2006, Besser, Chorin et al. 2009). Conversely, there have been a
few studies that suggest that zinc is not released in a fashion where it can interact with NMDA
receptors on the post-synaptic neuron, but rather that zinc coats the pre-synaptic membrane
(AR 2003, Kay and Tóth 2008, Nydegger, Rumschik et al. 2010). The vesicular zinc
transporter ZnT3 (Palmiter, Cole et al. 1996)has been found at glutamatergic synapses,
suggesting that zinc is loaded into the same synaptic vesicles as glutamate (Sindreu, Varoqui
et al. 2003). Knockout of ZnT3 results in mice that are more susceptible to seizures due to an
excess of excitatory transmission . Furthermore, mice with a knock-in mutation rendering
GluN2 subunits insensitive to zinc are hypersensitive to pain, suggesting that zinc does indeed
have a physiological synaptic role (Nozaki, Vergnano et al. 2011) and does travel across the
synaptic cleft.

2.2 Zinc Inhibition of NMDA receptors
Zinc is a voltage-dependent and a voltage-independent inhibitor of the NMDA receptor
(Paoletti, Ascher et al. 1997). Zinc pore-blocks the receptor at negative membrane potentials.
Mutations to the pore, including residues N616 in GluN1, N595 in GluN2A, N615 in GluN2A,
and N614 in GluN2A, result in a loss of zinc pore-block (Paoletti, Ascher et al. 1997, Hatton
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and Paoletti 2005, Amico-Ruvio, Murthy et al. 2011). Zinc binds to and inhibits all subtypes of
the GluN2 subunit in a voltage-independent fashion, with highest affinity for the GluN2A
subtype, intermediate affinity for the GluN2B subtype, and low affinity for the GluN2C and
GluN2D subtypes (Rachline, Perin-Dureau et al. 2005). The zinc binding site is composed of
histidines and aspartates in the cleft between the upper and lower lobes of the GluN2 ATD.
In the GluN2A ATD, two histidines in particular were identified as crucial to the zinc binding
site, His42 and His44 (Choi and Lipton 1999, Fayyazuddin, Villarroel et al. 2000); these
residues are not conserved in the GluN2B subtype. Additionally, His127 and Asp283 are
important to zinc binding, and these residues are conserved in GluN2B (His128 and Asp284
in GluN2B) (Rachline, Perin-Dureau et al. 2005, Karakas, Simorowski et al. 2009). Zinc
incompletely inhibits receptors composed of the GluN2A subunits, with maximal inhibition
ranging from 40-80% (Paoletti, Ascher et al. 1997, Choi and Lipton 1999, Paoletti, PerinDureau et al. 2000, Rachline, Perin-Dureau et al. 2005). Diheteromeric receptors containing
the GluN2B, GluN2C, or GluN2D subunits are inhibited completely by saturating
concentrations of zinc (Rachline, Perin-Dureau et al. 2005). The incomplete inhibition of
GluN2A subunits, which are the most common, coupled with the co-release of zinc with
glutamate suggests that zinc helps fine tune the final signal transmitted between neurons
during normal synaptic transmission.
Mechanistic work studying the nature of zinc inhibition found that the stability and
conformation of the ATD influences the Po of the receptor in general. The best supported
mechanism of zinc inhibition is that zinc inhibits by modifying the conformation of the ATD,
which allosterically destabilizes the gating machinery of the receptor. Cross-linking reagents
used to wedge open the cleft of the ATD showed that if the ATD cleft was more open, the
receptor was potentiated. The mechanism suggested was that by opening and closing the
ATD cleft, zinc affected the stability of the dimer interface of the LBDs (Gielen, Le Goff et al.
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Figure 2.1: Structures of the isolated GluN2B ATD. Shown are crystal structures of the
GluN2B ATD without (A) and with (B) zinc bound, PDB IDs 3JPY and 3JPW, respectively.
The residues highlighted in (B) are His128, Asp284, and Glu285 which coordinate zinc
binding. In panel C, the two crystal structures are aligned to each other. Both structures,
although one has zinc bound, captured the same structural state of the ATD. They align
with an RMSD of 0.368 Å.
2008). It was hypothesized that an open ATD cleft led to a greater activation of the receptor
(higher Po), whereas the receptor was inhibited when the cleft was closed (lower Po).
Structural advances have allowed us to visualize zinc in its binding site in the GluN2B ATD.
The cleft closure mechanism suggested by functional studies was not present in the crystal
structures, as the zinc-free structure of the ATD matched to the zinc-bound structure (Karakas,
Simorowski et al. 2009). The zinc-bound and zinc-free ATD structures aligned to each other
with an RMSD of 0.368 Å (Karakas, Simorowski et al. 2009); both structures captured the
closed-cleft conformation (Figure 2.1). The crystal structure, however, confirmed that in
GluN2B subunits, the zinc binding site was composed of His128, Asp283, and Glu284
(Karakas, Simorowski et al. 2009).
Work by the Paoletti lab identified the ligand-binding domain dimer interface, the same
interface identified as critical to gating of the AMPA and NMDA receptor, as an important
player in the mechanism of zinc inhibition (Gielen, Le Goff et al. 2008). Disrupting the
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hydrophobic interface at the ligand-binding domains shifts the zinc dose response curves
(reduces IC50) (Gielen, Le Goff et al. 2008). Conversely, stabilizing the LBD dimer interface
by the introduction of cysteine crosslinks results in a decreased ability of zinc to inhibit the
receptor.
Zinc was shown to have a very slow unbinding rate, on the order of milliseconds
(Paoletti, Ascher et al. 1997). Single-channel analysis of GluN1/GluN2A NMDA receptors
shows that zinc-bound receptors still proceed through modal gating (Amico-Ruvio, Murthy et
al. 2011), but the open state of the receptor is less stable resulting in shorter openings and a
lower open probability (Erreger and Traynelis 2008, Amico-Ruvio, Murthy et al. 2011).

2.3 Ifenprodil inhibition
Ifenprodil, a member of the class of phenylethanolamines, was identified as an inhibitor
of the NMDA receptor about 25 years ago. Ifenprodil underwent clinical trials as an NMDA
receptor antagonist but failed due to significant off-target effects (Chizh, Headley et al. 2001).
However, ifenprodil inhibition is still widely studied because it provides insight into subtype
specific inhibition of the NMDA receptor. For instance, ifenprodil has been conjugated to
fluorescent probes to allow for the specific detection of GluN2B subunits in cells (Williams

OH

1993, Marchand, Becerril-Ortega et al.
2012). Ifenprodil (Figure 2.2) has two

HO
N

ionizable functional groups: a tertiary
nitrogen with a pKa of 9.05 and a phenolic

Figure 2.2: Structure of Ifenprodil.

hydroxyl with a pKa of 9.66; ifenprodil
carries a positive charge on its tertiary

nitrogen group at physiological pH (Kobayashi, Washiyama et al. 2006). The binding site
remained elusive for some time, with many studies identifying residues within the ATD as
important to ifenprodil inhibition (Williams 1993, Gallagher, Huang et al. 1996, Masuko,
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Kashiwagi et al. 1999, Perin-Dureau, Rachline et al. 2002, Mony, Krzaczkowski et al. 2009).
Most recently, the crystal structure of the soluble GluN1-GluN2B ATD dimer showed that
ifenprodil bound at the interface between the two subunits’ ATDs (Karakas, Simorowski et al.
2011). Contacts with both subunits are critical to ifenprodil inhibition (Karakas, Simorowski et
al. 2011). Residues identified as crucial to ifenprodil binding in the crystal structure include
Ile82, Gln110, Ile111, and Phe114 in GluN2B and Ala75, Phe113, and Leu135 in GluN1
(Karakas, Simorowski et al. 2011, Tomitori, Suganami et al. 2012). An analog of ifenprodil,
Ro25-6981, was also found to bind to the same pocket between the ATDs (Karakas,
Simorowski et al. 2011). Given that many residues were identified that affect ifenprodil binding,
it is possible those mutations affected the electrostatics of the receptor, the proton binding
sites, or somehow altered the conformation of particular regions of the ATD resulting in a shift
in ifenprodil inhibition (Gallagher, Huang et al. 1996, Karakas, Simorowski et al. 2009, Mony,
Krzaczkowski et al. 2009, Tomitori, Suganami et al. 2012). Cross-linking studies suggest that
the mobility of the lower lobes of the ATDs is critical to ifenprodil’s ability to inhibit the NMDA
receptor (Karakas, Simorowski et al. 2011).
Functional analyses of single channels showed that ifenprodil reduces the open
probability of the NMDA receptor by increasing the barrier to activation (Amico-Ruvio,
Paganelli et al. 2012). Receptors bound by ifenprodil also had longer MCTs and shorter MOTs
(Amico-Ruvio, Murthy et al. 2011). Taken together, these data suggests that the binding of
ifenprodil to the ATDs and the ensuing conformational movements of the lower lobes of the
ATDs destabilize the gating machinery of the receptor, similar to zinc binding. However, direct
structural evidence of the conformational changes associated with ifenprodil inhibition are still
lacking. The crystal structure of the apo GluN2B ATD (PDB ID 3JPW), aligns to the GluN2B
ATD in the dimeric GluN1/GluN2B ATD structure (PDB ID 3QEL) with an RMSD of 0.618,
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further demonstrating that the crystal structures are only capturing one of the states that the
ATDs can adopt.

2.4 Spermine Potentiation
Another endogenous modulator of the NMDA receptor, the polyamine spermine, has
several effects on receptor function depending on its interaction site. Each spermine molecule
has four amine groups (Figure 2.3), two primary and two secondary, that are all protonated at
physiological pH, (has four amino groups with pKa values of 10.9, 10.1, 8.9, and 8.1) so
spermine carries several positive charges (Palmer and Powell 1974, Geall, Taylor et al. 2000,
Woster and University 2006). Spermine has many known roles in cellular processes
throughout the body (Morgan 1999), and in the central nervous system intracellular spermine
in neurons pore blocks ion channels. Spermine can pore block the NMDA receptor in a
subtype-independent manner. There is evidence that spermine is also released into the
synapse in an activity dependent fashion (Masuko, Kusama-Eguchi et al. 2003), so that
spermine can be an extracellular modulator of the NMDA receptor during normal synaptic
transmission. Spermine binding to the extracellular side of the NMDA receptor potentiates
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Figure 2.3: Structure of Spermine.

responses elicited by the agonist, with
NH2

specificity for GluN2B subtypes of the
NMDA receptor.
Spermine is thought to bind at

the interface between the lower lobes of the GluN1 and GluN2B ATDs. Deletion of either the
GluN1 or GluN2B ATD results in a loss of spermine potentiation, supporting the idea that
spermine binds at the interface between the two ATDs (Mony, Zhu et al. 2011). Mutating acidic
residues in the lower lobes of the GluN1 or GluN2B ATDs to basic residues results in a loss
of spermine potentiation (Masuko, Kashiwagi et al. 1999, Mony, Zhu et al. 2011). The basic
residues are likely unable to bind to the positively charged spermine. Splice variants of GluN1
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that contain exon 5, which sits in the lower lobe of the ATD, are insensitive to spermine
potentiation, even when the receptor is composed of GluN2B subunits. Exon 5 adds six basic
residues to the lower lobe of the GluN1 ATD, suggesting that the positive charges introduced
by exon 5 function similarly to spermine and obviate the spermine binding site (Durand,
Bennett et al. 1993, Traynelis, Hartley et al. 1995). Spermine binding to the extracellular
portion of the NMDA receptor also results in an increase in apparent glycine affinity (K., Zappia
et al. 1994). Independent of the effect on glycine affinity, spermine increases the frequency of
channel openings in single channel recordings from neurons (Rock and MacDonald 1992).
When a bulky thiol-reactive group is bound within the GluN2B cleft, Mony, et al.,
showed that spermine no longer potentiates the receptor, suggesting that spermine stabilizes
an open-cleft conformation of the GluN2B ATD (Mony, Zhu et al. 2011). If the cleft is already
propped open, spermine cannot do any more to the receptor. Spermine seems to potentiate
the receptor by employing the opposite mechanism of zinc, which inhibits the receptor by
closing the ATD cleft. Since spermine binds at the GluN1/GluN2B interface at the ATDs and
specifically potentiates receptors that contain GluN2B, one possible explanation of the
specificity is that there is something unique about the GluN1/GluN2B ATD dimer interface that
allows for the specificity. Another possibility is that GluN2B containing receptors have an
inherent structural feature, including the opening of the bi-lobed ATD cleft, that is unique and
allows spermine to potentiate the receptor. GluN2A containing receptors could have a more
open ATD cleft to begin with, potentially explaining why spermine does not potentiate and why
GluN2A containing receptors have inherently higher open probabilities. Chimeras that swap
the ATDs of GluN2A and GluN2B confirm that the specificity of binding is to the GluN2B ATD.
Interestingly, as noted when studying zinc inhibition, swapping the linker that connects the
ATD to the ligand binding domain is necessary to fully swap the function of the subunit to that
of its counterpart (Gielen, Retchless et al. 2009, Mony, Zhu et al. 2011). Spermine potentiation
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proceeds by stabilizing the open state of the receptor, reducing the rate of entry into
desensitization, and increasing the rate of recovery from desensitization (Rumbaugh,
Prybylowski et al. 2000).

2.5 Proton Inhibition
Synaptic transmission is known to change pH at the synaptic cleft. When
neurotransmitters are initially released, there is a slight acidification of the synaptic cleft,
followed by a slight alkilination. Proton concentrations are tightly regulated and important at
the synapse because proton gradients are necessary to the process of loading
neurotransmitters into synaptic vesicles. The pH changes on the order of 0.1-0.2 units,
changes that are enough to alter the function of the NMDA receptor. Protons inhibit the NMDA
receptor (Giffard, Monyer et al. 1990, Tang, Dichter et al. 1990, Traynelis and Cull-Candy
1990, Traynelis and Cull-Candy 1991), and the proton IC50 is at physiological pH (Traynelis,
Hartley et al. 1995). Many studies have tried to identify the proton sensor, and tens of residues
have been identified throughout the GluN1 and GluN2 subunits, including exon 5 of GluN1
(Traynelis, Hartley et al. 1995, Keiko, Fukuchi et al. 1996, Low, Lyuboslavsky et al. 2003).
Some of the residues identified do not have ionizable side chains, suggesting their mutation
disrupts coordination of water or other properties of the receptor. Deletion of the ATD does
not abolish proton inhibition, although it does shift the IC50 (Gielen, Retchless et al. 2009).
Proton inhibition of the NMDA receptor is closely tied to modulation of the receptor by
zinc, ifenprodil, and spermine (Mott, Doherty et al. 1998, Traynelis, Burgess et al. 1998, Mony,
Zhu et al. 2011). The NMDA receptor is more greatly inhibited by zinc and ifenprodil at lower
pHs, suggesting that zinc and ifenprodil sensitize the receptor to protons (Traynelis, Burgess
et al. 1998, Low, Zheng et al. 2000). Ifenprodil inhibits less at more alkaline pHs, although it
is still able to bind (Mott, Doherty et al. 1998). Conversely, spermine potentiates the receptor
more at lower than at higher pHs, suggesting that spermine potentiates the receptor by
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relieving proton inhibition. It remains unclear what the structural mechanism is that links these
processes. It is possible that the binding of protons modifies the overall surface electrostatic
charges on the surface of the receptor, thereby altering the environments of the binding sites
of the other modulators. Binding of the other modulators could reverse this shift, in addition to
the conformational changes they are known to induce. The residue H128 in GluN2A has been
shown to affect both zinc inhibition and proton inhibition of the receptor (Low, Zheng et al.
2000). This residue is potentially a link between the zinc and proton binding sites.

2.6 The Role of the GluN1 ATD
The GluN1 ATD is important to allosteric modulation of the NMDA receptor, although
there are no known ligands that bind only to the GluN1 ATD. Deletion or cleavage of the GluN1
ATD results in decreased zinc inhibition of NMDA receptors composed of GluN2A or GluN2B
subunits (Madry, Mesic et al. 2007). Further, deletion of the GluN1 ATD abolishes spermine
potentiation of the receptor. The GluN1 subunit, as mentioned above, can be one of eight
splice variants. Exon 5 is in the lower lobe of the GluN1 ATD, is 21 amino acids long, and has
six basic residues. The sequence of exon 5 is ‘SKKRNYENLDQLSYDNKRGPK’. The
inclusion of exon 5 greatly alters the affinity to allosteric modulators. The zinc and proton doseresponse curves for GluN1-GluN2B receptors are right-shifted when exon 5 is included,
meaning that zinc and protons have a lower affinity for the GluN2B subunit (Traynelis, Hartley
et al. 1995, Traynelis, Burgess et al. 1998). As mentioned above, spermine no longer
potentiates the receptor when exon 5 is included in GluN1. Mutations in GluN1 have been
identified that shift ifenprodil and pH IC50s, solidifying both a role for GluN1 in allosteric
modulation and a link between proton and ifenprodil modulation (Mott, Doherty et al. 1998).
The fact that GluN1 ATD deletion results in abolished zinc inhibition is particularly
interesting given that the zinc binding site is entirely contained in the GluN2 ATD and that zinc
binding has been found to influence glutamate affinity but not glycine affinity in GluN2A
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containing receptors (Zheng, Erreger et al. 2001, Erreger and Traynelis 2005). However,
deleting either the GluN1 or GluN2B ATD in a GluN1/GluN2B diheteromeric receptor reduces
glycine potency (Madry, Mesic et al. 2007). Propping open the GluN1 ATD results in a
potentiation of the GluN1/GluN2B receptor (Zhu, Stroebel et al. 2013), suggesting that the
GluN1 ATD is flexible and its conformational state can influence that of the receptor as a
whole. Despite the lack of ligands binding solely to the GluN1 ATD, it is plausible that the
GluN1 ATD is critical to the mechanism of modulation, if only to serve as a wedge that holds
the GluN2 ATD in a particular state. Modulators such as ifenprodil and spermine, which bind
at the interface of the GluN1/GluN2B ATDs, may directly alter the conformation of the GluN1
ATD, a question that remains unanswered. The contacts that could form between the GluN1
and GluN2 ATDs during modulation could be critical to stabilizing a particular state and
effecting modulation.

2.7 Allosteric Modulation and Its appeal for subtype specific pharmacology and
drug design – Rationale behind project
NMDA receptors, as mentioned above, play an integral role in learning and memory
formation. Aberrant activation of NMDA receptors is implicated in a variety of neurological
disorders. NMDA receptor overactivation during ischemic stroke leads to neurotoxicity and
neuronal cell death. NMDA receptor hypoactivation is implicated in schizophrenia. NMDA
receptor dependent neurotoxicity is also implicated in Huntington’s disease, Alzheimer’s
disease, Parkinson’s disease, depression, and neuropathic pain (reviewed in (Traynelis,
Wollmuth et al. 2010)), although the exact mechanism of involvement in these conditions
remains largely unknown. Given the variable expression of different subtypes of the GluN2
subunits, many in the field have focused on subtype specific modulators as a promising
avenue for drug design. The hope is that subtype specific modulation will inhibit or potentiate
specific receptors in a disease state without impacting normal synaptic transmission.
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Ifenprodil, a synthetic compound, was discovered to be a GluN2B specific NMDA receptor
inhibitor in the late 1980s (C., Benavies et al. 1988). Ifenprodil failed clinical trials due to
significant binding and inhibition of cardiac calcium channels (Chizh, Headley et al. 2001).
However, ifenprodil has remained a popular subject of study in attempts to understand the
structural and functional mechanism of inhibition. Further, modulators that bind to any part of
the receptor in a subtype specific fashion remain the subject of intense study for this exact
reason. Given that NMDA receptors exist predominantly as triheteromeric species (Tovar,
McGinley et al. 2013), combining two GluN2 subtypes, subtype specific modulators may
indeed provide a fine-tuning of NMDA receptor signaling without modulating signaling as a
whole. This rationale motivates our experiments to understand the structural mechanism of
allosteric modulation of the receptor, in hopes that if we understand the structural mechanism,
we could identify hot-spots of the receptor that could be targeted by future drug design
attempts.
Within the hippocampus, the region of the brain responsible for memory formation and
consolidation, GluN2A is the most prevalent subtype, as mentioned above, and it was at
hippocampal neurons that it was discovered that zinc was released in an activity dependent
fashion. As such, it is very physiologically relevant to study zinc inhibition as these receptors
are likely inhibited at the same time that the receptor is being activated. After studying zinc
inhibition, we wanted to determine if the structural mechanism of zinc inhibition was
generalizable to other allosteric inhibitors that bind to other sites on the ATD or if it was
dependent on zinc binding within the cleft of the ATD. To answer this question, we looked at
ifenprodil inhibition of receptors composed of the GluN2B subunit. By switching to the GluN2B
subunit, we could compare allosteric inhibition of different subtypes (GluN2A vs. GluN2B) and
for inhibitors with different binding sites (zinc vs. ifenprodil). Moreover, as explained above,
the mechanism of spermine potentiation is poorly understood, except that it is thought to
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proceed in the opposite structural mechanism of zinc inhibition. We are aptly situated to
address these questions using a combination of fluorescence spectroscopy to characterize
structural changes and functional studies to correlate structure to function.
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Chapter 3:
Theory Underlying Luminescence Resonance
Energy Transfer (LRET)

The text and figures of this chapter are modified and reprinted with permission from a
book chapter which is in press: Sirrieh, R. E. and V. Jayaraman (2015). LRET Methods
for Investigating Conformational Changes in Functional Glutamate Receptors.
Ionotropic Glutamate Receptor Technologies. G. K. Popescu, Springer Business +
Science Media.
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Luminescence resonance energy transfer (LRET) was used extensively to monitor
conformational changes induced by ligand binding and to characterize inherent structural
conformations. LRET is an invaluable tool to study the conformational changes of proteins
induced by ligands or protein-protein interactions at Ångstrom level resolution. LRET
experiments require a pair of fluorophores with overlapping spectra, where the emission of
the ‘donor’ overlaps with the excitation of the ‘acceptor’ fluorophore. The efficiency of nonradiative energy transfer can be determined by measuring the sensitized emission of the
acceptor fluorophore, upon exciting the donor fluorophore. The efficiency of transfer, in turn,
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Figure 3.1: LRET requires fluorophores with overlapping spectra. Shown are the
excitation and emission curves of terbium chelate in dashed and solid black lines,
respectively. The excitation and emission peaks of Alexa555 are shown in dashed and
solid green lines, respectively. In order for LRET to occur, the emission of the donor,
terbium chelate, and the excitation of the acceptor, Alexa555, must overlap. The integral
of the overlap between the two curves is called the overlap integral and is required to
calculate the R0 for the pair of fluorophores.
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can be correlated to the distance between the two fluorophores. A modification of the LRET
technique, whereby the LRET lifetime is measured before and after protease cleavage of the
receptor, allows for the quantification of background fluorescence and for measurements to
be made in functional receptors expressed in mammalian cells (Prithwish Pal, Brian E.
Holmberg et al. 2005, Gonzalez, Rambhadran et al. 2008, Rambhadran, Gonzalez et al. 2011,
Sirrieh, MacLean et al. 2013). The specific LRET lifetime that can be measured in this system
can be used to describe conformational changes associated with gating, allosteric modulation,
inhibition, partial agonism, protein-protein interactions, and inter-subunit interactions
associated with motions of the receptor. By subsequently coupling this technique with
functional characterization of the receptor, a direct connection can be drawn between
structural changes and the functional consequences.
LRET is a modification of fluorescence resonance energy transfer (FRET) which relies
on the same underlying principle of non-radiative energy transfer between a pair of
fluorophores dependent on the distance between the two fluorophores (Forster 1946, Stryer
and Haugland 1967). Essentially, two fluorescent molecules with overlapping spectra, where
the emission spectrum of the ‘donor’ overlaps with the excitation spectrum of the ‘acceptor,’
are introduced at particular sites on a macromolecule (Figure 3.1). The efficiency of energy
transfer between these two fluorescent molecules can be directly correlated to the distance
between the fluorophores using the Förster equation (Forster 1946) (Eq. 3.1), where R0 is the
distance at which there is 50% energy transfer between the two fluorophores,
of the donor in the absence of the acceptor, and

DA

D

is the lifetime

is the sensitized acceptor lifetime. The

temporal resolution afforded by luminescence allows for the separation of the LRET lifetime
(on the order of microseconds) from receptors labeled only with acceptors (on the order of
nanoseconds) and receptors labeled only with donors (on the order of milliseconds).
Equation 3.1

/
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Distances that can be measured with a particular pair of fluorophores technically range
from 0.5R0 to 1.5R0 (dos Remedios and Moens 1995); therefore, the fluorophore pair should
be chosen so that the distance range being measured is within this range of the R0 (Table
4.2). Additionally, it is best to choose a pair of fluorophores so that the expected sensitized
acceptor emission lifetimes are 100-500 µs. Lifetimes within this range allow you to easily
subtract out background with a long lifetime due to donor bleed through (800-1500 µs) and
the lifetime is not too short so that it aligns with the laser line. The laser line is an intense peak
due to light scatter off the cells or bleed-through of the excitation pulse.

Fluorophore
(company purchased
from)

Excitation
Maximum (nm)

Emission
Maxium (nm)

R0 with Terbium
chelate (Å)

ATTO465
(Invitrogen)

453

508
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Fluorescein
(Fluka)

492

515

45

Alexa555
(Sigma Aldrich)

555

565

65

Ni(NTA)2Cy3
(bis-reactive Cy3 from
GE Healthcare)

550

572

65

Table 3.1: Fluorophores used in LRET experiments. Given are the names of the
fluorophores used, the company from which each was purchased, the excitation and
emission wavelengths, and the R0 of the fluorophore with terbium chelate.
Equation 3.2

.

∗

∗

∗

∗

R0 depends on the orientation of the fluorophores (κ), the quantum yield of the donor
(ϕD), the overlap integral (J), and the refractive index (n) (Eq. 3.2). The quantum yield of the
donor is the ratio of the number of photons emitted to the number of photons absorbed. The
overlap integral depends on the pair of fluorophores selected, and an example is shown in
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Figure 3.1 where the overlap integral is the integral of the area beneath the overlapping curves
between the solid black line and the dotted green line. The refractive index used for biological
solutions is 1.4 (dos Remedios and Moens 1995). The orientation factor (κ2) can be
approximated to a value of 2/3 assuming isotropic fluorophores. The error due to this
assumption is minimized as the donor terbium is isotropic. Furthermore, the error in the
absolute distance can be determined by measuring anisotropy for the acceptor fluorophore. It
should be noted that these errors are errors in the absolute distances. The error is further
reduced when measuring changes in distances, assuming a similar distribution in the two
states being measured.
LRET offers several advantages over FRET that arise from the use of lanthanides as
the donor fluorophores. These lanthanides undergo forbidden f-orbital electron transitions
upon excitation, and their emission is neither fluorescent nor phosphorescent (Selvin 2002).
Since the excited state is still inducing an electric dipole, they can transfer energy to organic
fluorophores (Selvin 2002), which we use as the acceptor fluorophores to form LRET pairs.
Of the lanthanides, terbium is the most commonly used donor fluorophore. Lanthanides have
a long, easily quantified donor only lifetime (Chen and Selvin 1999), four main emission peaks
that can be combined with various acceptor fluorophores (Figure 3.1), and narrower emission
peaks relative to broad fluorescence peaks, which allows for the investigation of changes at
the acceptor wavelength with little or no bleed-through from the donor emission in the acceptor
channel. Most importantly, though, as mentioned above terbium is isotropic, so the error
associated with the orientation factor κ2 (Eq. 3.2). The wide availability of maleimideconjugated fluorophores and chelates of lanthanides has greatly facilitated specific labeling
of receptors. Non-disulfide bonded cysteines in the receptor are conservatively mutated to
serines so that they will not be labeled, and subsequent introduction of cysteines means that
fluorophores will be bound at the sites of choice. While this labeling technique provides a
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convenient and relatively straightforward method for introducing the fluorescent tags, one of
the early limitations of this methodology is that proteins could not be studied in non-purified
systems as other proteins on the cell surface also contain cysteines which will be labeled with
the fluorophores. In order to overcome this problem we have adapted a modification to the
LRET technique, wherein a protease recognition sequence is introduced in the receptor
between the donor and acceptor label sites (Gonzalez, Rambhadran et al. 2008, Gonzalez,
Du et al. 2010, Rambhadran, Gonzalez et al. 2010, Rambhadran, Gonzalez et al. 2011,
Sirrieh, MacLean et al. 2013). Either the recognition sequence for thrombin (LVPRGS) or
Factor Xa (IDGR or IEGR) is used. Measuring the LRET lifetime before and after protease
cleavage thus allows for the quantitative characterization of the signal specific to the protein
being investigated. The introduction of two cysteines in the receptor to be labeled means that
the two cysteines will be labeled through the same binding chemistry, and there is no way to
know to which site is bound to the ‘donor’ fluorophore or the ‘acceptor’ fluorophore. However,
this ambiguity does not impact the experiment, because, on average, the experiment is
measuring a change in the LRET signal under different ligated conditions. Once the receptors
are labeled, any change in the observed lifetime has been induced by the ligand, rather than
any differences in the orientation or location of the fluorophore, which remains covalently
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Figure 3.2: Lifetime versus distance in LRET. A
representative curve of distance vs. lifetime for a pair of
fluorophores with an R0 of 45 Å highlights the direct relationship
between energy transfer and distance.
bound to the same site throughout the experiment. Given the known acceptor fluorophores,
when paired with terbium chelate as the donor, the distance range that can be measured with
LRET is 20-90 Å. A sample curve of sensitized acceptor lifetime versus distance for an R0 of
45 Å is shown in Figure 3.2 and was calculated by assuming a donor only lifetime ( D) of 1700
µs.
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Chapter 4:
Methods

Some of the text in this chapter was originally published in the Journal of Biological Chemistry. The text has
been modified and reprinted with permission from Sirrieh, R.E., MacLean, D.M., Jayaraman, V. Aminoterminal Domain Tetramer Organization and Structural Effects of Zinc Binding in the N-Methyl-D-aspartate
(NMDA) Receptor. Journal of Biological Chemistry. 2013; 288: 22555-64. © The American Society for
Biochemistry and Molecular Biology.
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4.1 Soluble Protein Expression and LRET Analysis
Spodoptera frugiperda (Sf9) cells were maintained in media supplemented with 10%
FBS and penicillin/streptomycin and passaged every two days. Sf9 cells were used to produce
a baculovirus that could be used to express the soluble ATD of the NMDA receptor. Bacmid
DNA containing the GluN2A or GluN2B ATD was cotransfected with BaculoGold viral DNA
(BD Biosciences) into the Sf9 cells using the Cellfectin Transfection reagent (Life
Technologies). The ATD construct had retained Cys231 in GluN2A or Cys232 in GluN2B.
Additionally, at the N-terminus of each construct, there had been inserted a cysteine, an octahistidine tag, and the thrombin recognition sequence (LVPRGS). The GluN2B construct was
provided by Dr. Hiro Furukawa, and the GluN2A construct was prepared using traditional PCR
methods. Further, both constructs contained the human placental alkaline phosphatase
secretion signal at the very N-terminus of the construct so that the synthesized protein would
be secreted into the media. The initial virus (P0 generation) was successively amplified in Sf9
cells. Hi5 cells were maintained in serum-free media and passaged every two days.
Baculovirus generated in Sf9 cells was used to infect Hi5 cells. Cells were cultured to a volume
of 200-300 mL and were allowed to express protein for 2 days before the media, which
contained the protein, was harvested. The media was concentrated using an Ambion spin
column, and the remaining solution was used for protein purification. Either a nickel column
attached to an FPLC system or nickel beads were used to purify the protein via the his-tag
attached at the N-terminus. Protein was maintained in 200 mM NaCl, 20 mM Tris, pH 8.0 as
previously described (Karakas, Simorowski et al. 2009). SDS-PAGE was used to ensure that
the protein was present and to check purity. Protein was labeled overnight at 4°C, dialyzed
for 3-4 hours the following morning, and then used for the LRET experiments. The buffer used
was always 200 mM NaCl, 20 mM Tris, pH 8.0.
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4.2 Isothermal Titration Calorimetry
To verify that the soluble ATD protein was functional, isothermal titration calorimetry (ITC) was
performed with a VP-ITC instrument (MicroCal). Two milliliters of protein at a 20 µM
concentration was inserted into the chamber and titrated by 40 injections of 5 µL of 0.8 mM
zinc chloride at 27 °C, as described previously (Karakas, Simorowski et al. 2009). The
enthalpy change due to binding would be detected by the instrument, by measuring how much
energy was required to maintain the chamber temperature.

4.3 Cloning and Mutagenesis
All full-length receptor constructs were in pcDNA3.1 vectors. To specifically label receptors
with maleimide-derived fluorophores, all non-disulfide-bonded cysteines, as identified from
existing crystal structures and previous work in our laboratory (18, 19), were mutated to
serines: C22S and C459S for GluN1 (called GluN1*), C231S, C395S, and C461S for GluN2A
(called GluN2A*), and C232S, C399S, and C495S for GluN2B (GluN2B*). Further mutations
were made on these base constructs, unless an inherent cysteine was retained to be labeled.
A list of all constructs and the mutations they contain is found in Table 4.1. Mutations were
made using traditional PCR methods, and the integrity of the plasmid and insert were verified
by sequencing. To measure distance changes in full-length receptors in intact membranes
without protein purification, the thrombin (LVPRGS) or Factor Xa (IDGR or IEGR) recognition
sequence was introduced between donor and acceptor fluorophores, as discussed in Chapter
3.
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Construct Name

Mutations

GluN1*

C22S, C459S

Construct
Coexpressed
With
GluN2Acleft
GluN2Bcleft

Acceptor
Fluorophore
Ni(NTA)2Cy3

GluN2B*H30
GluN2B*232
GluN2B*210
GluN2A*H30
GluN2A*231
GluN2A*211

Ni(NTA)2Cy3
Alexa555
Fluorescein
Ni(NTA)2Cy3
Alexa555
Fluorescein

GluN2B*,
GluN2A*

Alexa555

GluN1cleft

Alexa555

GluN2A*C30

C232S, C395S, C461S,
insertion of a Cys followed
by amino acids LVPRGS
after residue 30

GluN1*C22

Alexa555

GluN2A*H30

C232S, C395S, C461S,
insertion of hexa-his tag
followed by amino acids
LVPRGS after residue 30

GluN1*C22

Ni(NTA)2Cy3

GluN2Acleft

C395S, C461S, insertion
of hexa-his tag followed by
amino acids LVPRGS after
residue 30

GluN1*

Ni(NTA)2Cy3

GluN2ADHM

H44A, H128S, C395S,
C461S, insertion of hexahis tag followed by amino
acids LVPRGS after
residue 30

GluN1*

Ni(NTA)2Cy3

GluN2A*231

C395S, C461S

GluN1*C22

Alexa555

GluN2A*210

C232S, C395S, C461S,
D210C

GluN1*C22

Fluorescein

GluN2B*

C232S, C399S, C495S

GluN1cleft

Alexa555

GluN1*C22

GluN1cleft
GluN2A*

C459S

insertion of the amino
acids LVPRGS after
residue Cys22, C459S,
S224C
C232S, C395S, C461S
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GluN2B*H30

C232S, C399S, C495S,
insertion of hexa-his tag
followed by amino acids
LVPRGS after residue 30

GluN1*C22

Ni(NTA)2Cy3

GluN2Bcleft

C399S, C495S, insertion
of hexa-his tag followed by
amino acids LVPRGS after
residue 30

GluN1*

Ni(NTA)2Cy3

GluN2B*231

C399S, C495S

GluN1*C22

Alexa555

GluN2B*210

C232S, C399S, C495S,
D210C

GluN1*C22

Fluorescein

Table 4.1: Constructs used for experiments. Given in this table are the names of the
constructs used for LRET experiments, the mutations each construct includes, the
construct it was co-expressed with, and the acceptor fluorophore used for that pair of
constructs.

4.4 Fluorophores
The donor fluorophore used was always terbium chelate (Invitrogen), and the acceptor
fluorophores were ATTO465 (Invitrogen), Fluorescein (Fluka), Alexa Fluor 555 (SigmaAldrich) or Ni(NTA)2Cy3. See Table 3.1 for the corresponding R0 values with terbium chelate
and the excitation and emission wavelengths. Ni(NTA)2Cy3 was prepared as described
previously (22) using bis-reactive Cy3 purchased from GE Healthcare. Free NTA (Dojindo
Laboratories) was conjugated to the bis-reactive Cy3 dye in 0.1 M sodium carbonate. The
doubly conjugated product was purified using preparative thin layer chromatography (TLC)
and then conjugated to nickel. Excess nickel was removed and the final product was dried,
resuspended in water, and the concentration was quantified.

4.5 Protein expression in Xenopus laevis oocytes
Full-length receptors were expressed in Xenopus laevis oocytes as described
previously (23). X. laevis frogs who had been acclimated to their habitat for at least six weeks,
were anesthetized with 0.15% Tricaine solution (Sigma-Aldrich). At the site where the incision
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was to be made, the skin was injected with Bupivicaine to minimize post-operative pain.
Oocytes were then surgically removed, manually sheared into small clusters of oocytes, and
defolliculated in type II collagenase (Worthington) for 2-4 hours at room temperature. Stage
V and VI oocytes, which could be identified because of their relatively large size and distinct
black and white hemispheres, were selected and stored in Barth's solution containing 88 mM
NaCl, 2.5 mM NaHCO3, 1.1 mM KCl, 0.4 mM CaCl2, 0.3 mM Ca(NO3)2, 0.8 mM MgCl2, 2.5
mM sodium pyruvate, 10 mM HEPES, pH 7.3, and 5 μg/mL gentamicin at 12 °C. Plasmid DNA
of the mutant receptor in pcDNA 3.1 was linearized using a restriction enzyme that cut the 3’
end of the NMDA gene insert. GluN1 constructs were linearized with HindIII and GluN2A
constructs were linearized with XbaI (restriction enzymes from New England Biolabs). This
linearized DNA was gel purified and then used as the template with the Ambion T7 mMessage
mMachine Kit to produce the RNA. RNA was freshly prepared each time oocytes were to be
injected. Each oocyte was injected with 20 ng of RNA at a GluN1:GluN2 ng ratio of 1:2 (23).
Oocytes were allowed to recover at 12 °C for 12–24 hours. Oocytes were then induced at 18
°C and preblocked with 1 mM β-maleimidopropionic acid for 1 hour, which limited the number
of free cysteines on the surface of the oocytes and subsequently helped reduce nonspecific
labeling with the thiol-reactive fluorophores. Additionally, upon induction, oocytes were
maintained in saturating concentrations of 5,7-dichlorokynurenic acid (DCKA) to prevent
cytotoxicity due to overactivation of expressed NMDA receptors. One day after induction,
oocytes were labeled with 2 μM each of donor and acceptor fluorophores for 1 hour at 18 °C
and then washed three-five times with Barth's solution. Membrane fractions were prepared
using a lysis buffer composed of 20 mM Tris-Cl, pH 8.0, 200 mM NaCl, 1% Triton X-100, and
EDTA-free Complete Protease Inhibitor Mixture (Roche Diagnostics) in Barth's solution.
Oocytes were homogenized using a Douncer, and the cell lysate was centrifuged for 15
minutes at 13,000 rpm and 4 °C to isolate the soluble membrane fraction. The final volume of
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the membrane fraction was then brought up to 2–3 mL with Barth's solution and used for LRET
analysis.

4.6 Protein Expression in CHO cells
Chinese hamster ovary (CHO-K1) cells (ATCC) were maintained in Ham's F12
Nutrient

Mix

(Invitrogen)

supplemented

with

10%

FBS

(Sigma-Aldrich)

and

penicillin/streptomycin (Invitrogen). Cells were passaged once they reached a confluence of
80–90%, approximately every 2 days. CHO cells were transfected using Lipofectamine 2000
(Invitrogen) with 5–12 μg of DNA per 10-cm dish, at a GluN1:GluN2 μg ratio of 1:3 (20), a
DNA:Lipofectamine ratio of 1:2, and when cells were 50–80% confluent. To induce expression
of the NMDA receptor, cells were maintained in glutamine-free DMEM (Invitrogen) (21) for 1–
2 hours prior to transfection through their harvest for use in spectroscopic studies. Cells were
allowed to express for at least 40 hours in the presence of saturating concentrations of the
inhibitor DL-2-Amino-5-phosphonopentanoic acid (DL-APV) before being harvested, labeled,
and used for LRET studies. Cells were collected in extracellular buffer containing 1 mM CaCl2,
150 mM NaCl, 2.8 mM KCl, 10 mM HEPES, and EDTA-free Complete Protease Inhibitor
Mixture (Roche Diagnostics), pH 7.3–7.4 (HCl). CHO cells were labeled for 1 hour at room
temperature on a rotator in the dark using 200 nM each of the donor and acceptor fluorophores
in a 2–3-mL volume. Cells were washed twice after labeling to remove excess fluorophores
and then resuspended in extracellular buffer for LRET analysis.

4.7 LRET
Labeled cells or oocyte membrane fractions were probed in a cuvette-based LRET
analysis using a QuantaMaster model QM3-SS with Fluorescan software (Photon Technology
International). Data were analyzed with Origin 8.6 software (OriginLab Corp.). The lifetime of
the sensitized acceptor emission was measured upon directly exciting the donor. Donor-only
samples were excited at 337 nm, and emission was collected at 545 nm. Donor-acceptor45

labeled samples were excited at 337 nm, and the emission was collected at the indicated
wavelength for the given acceptor fluorophore (Table 4.2). A Peltier TE temperature controller
maintained the temperature at 15-20 °C for all recordings.
Because these receptors were expressed in nonpurified systems of CHO cells and X.
laevis oocytes, we employed a well-established technique to subtract background
fluorescence from our lifetime measurements, as discussed in Chapter 3. Specifically, after
obtaining acceptor lifetime measurements, five units of high activity bovine thrombin
(Calbiochem) or 3 µL of Factor Xa (New England Biolabs) were added to the cuvette and
allowed to cleave the receptor; cleavage was complete 2–3 hours following addition of the
protease. Any fluorescence detected following protease cleavage was considered
background fluorescence due to labeling of other surface proteins and was subtracted from
measurements obtained before cleavage.
Paoletti et al. demonstrated that zinc contaminates buffers in the nanomolar range,
and considering the high affinity of GluN2A subunits for zinc, it is probable that contaminating
zinc would bind to expressed receptors (Paoletti, Ascher et al. 1997). As such, all
measurements in CHO cells were also measured in the presence of 10 mM Tricine to ensure
any contaminating zinc did not affect our measurements. Tricine was used as opposed to
other chelators because, despite its relatively low affinity for zinc (Kd ≤ 10-9.7 M), it has an
even lower affinity for calcium and barium, therefore minimizing the effect of the chelator on
the buffer while still removing contaminating zinc. Zinc-bound measurements were made in
the absence of Tricine and in the presence of 5–10 μM zinc chloride (Sigma). This
concentration of zinc ensures that zinc-bound conformations of the ATD are maximally
populated. Glutamate-glycine measurements were collected by adding glutamate and glycine
to a final concentration of 1 mM and 100 μM, respectively, to zinc-bound receptors. Spermine
solutions were carefully buffered to ensure that the final pH was the same as that of the
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extracellular buffer used to re-suspend the cells and was added to a final concentration of 5
mM. Ifenprodil was added to cells at a final concentration of 10 µM.
Distances were calculated using the Förster equation (Equation 3.1), as described in
Chapter 3. N values represent the number of biological repeats. Each sample (n) was scanned
a minimum of three times, and each scan was an average of 99 sweeps. The lifetime was
detected for at least three times the expected LRET lifetime, with adjustments made as
needed after the first experiment, so that any longer components in the lifetime would not be
missed. The error in the LRET lifetime is the SEM, and the error in the distances was
calculated by propagating the errors in the lifetimes using the Error Propagation Calculator
developed by Thomas Huber in the Physics Department of Gustavus Adolphus College.

4.8 Electrostatics
For the full-length electrostatics, the recent crystal structure of the rat form of the
NMDA receptor (PDB ID 4TLL) was used as the template (Lee, Lü et al. 2014), and the Swiss
Protein Modeler was used with the primary sequence of the NMDA receptor to build .pdb files
that contain all side chains for residues in the structure. This modeling was necessary because
the electrostatics of the protein could not be calculated without the side chains of the amino
acids. For the isolated ATDs, the GluN2B ATD (PDB ID 3JPW) was the template for modeling
the GluN2A primary sequence, again using the Swiss Protein Modeler. The pdb2pqr converter
was used to generate a .pqr file (Dolinsky, Nielsen et al. 2004, Dolinsky, Czodrowski et al.
2007). This file was opened in VMD and the APBS plugin was used to calculate the surface
electrostatics of the NMDA receptor tetramer. The APBS plugin works by solving the PoissonBoltzmann equation for the surface charges of the protein (Baker, Sept et al. 2001).

4.9 Electrophysiology
All electrophysiology experiments were performed by Dr. David M. MacLean. CHO
cells were transfected using Lipofectamine 2000 (Invitrogen) with wild-type or mutant GluN1,
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GluN2A and enhanced GFP at a µg ratio of 1.25:3.75:1, respectively, with 6 µg of total DNA
per 10 mL of media, or with wild-type or mutant GluN1, GluN2B, and enhanced GFP at a μg
ratio of 1.5:4.5:1, respectively, with 7 μg of total DNA per 10 mL of medium. Following a 1012 hour incubation with transfection reagents, cells were plated at low density onto petri dishes
coated with poly-D-lysine. 300-400 µM DL-APV and 30 µM DCKA were present in the media
during and after transfection. Whole cell patch clamp recordings were performed 24-48 hours
post-transfection using borosilicate glass pipettes with 3-5 MΩ resistance, coated with dental
wax, fire polished and filled with the following solution (in mM): 135 CsF, 33 CsOH, 2 MgCl2,
1 CaCl2, 11 EGTA and 10 HEPES, pH 7.4. The external solution was (in mM): 140 NaCl, 2.8
KCl, 1 CaCl2, 10 HEPES, and 10 Tricine, pH 7.4 for measurements of zinc inhibition. The
external solution was (in mM): 140 NaCl, 2.8 KCl, 1 CaCl2, 10 HEPES, pH 7.4 for
measurements of spermine potentiation or ifenprodil inhibition. Free Zn2+ solutions up to 1 µM
were made as described by Paoletti et al., 1997, with 10 µM zinc added to an external solution
lacking tricine (Paoletti, Ascher et al. 1997).
Control, agonist, and agonist plus modulator solutions were locally applied to isolated
cells using a solenoid valve system (VC-6, Warner Instruments) and modified theta or quad
barrel tubing as previously described (Tang 2001). Glycine (100 µM) was present continuously
and glutamate (100 µM) was applied for 12 seconds every 20 seconds. To isolate the voltageindependent component of Zn2+ block, glutamate applications were performed at +50 mV with
series resistance compensated by 60-80%. For measurements of spermine potentiation,
glycine (100 μM) was present continuously, glutamate (100 μM) was applied for 12 s every
30 s, and saturating spermine (5 mM) was applied for 3 seconds during the glutamate pulse.
Cells were held at -60 mV prior to ligand application, ramped up to +50 mV several seconds
before glutamate application, maintained at this voltage during the application and then
ramped down to -60 mV and held between sweeps. All recordings were performed using an
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Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA), acquired at 10 kHz using
pCLAMP10 software (Molecular Devices), and filtered online at 3 kHz (8-pole Bessel,
Frequency Devices). All experiments were performed at room temperature.
For Zn2+ dose-response curves, Zn2+ inhibition was calculated as the steady-state
current at the end of the glutamate-Zn2+ application (I) divided by the current at the end of the
glutamate-only application (Imax). Data from each cell were fit with the following equation:
Equation 4.1
where a, IC50 and n are the residual, the half-maximal inhibition concentration, and the Hill coefficient, respectively.
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Chapter 5:
LRET on Isolated GluN2A and GluN2B ATDs
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The ATDs contain the binding sites of small molecule allosteric inhibitors such as zinc.
While zinc inhibits NMDA receptors through a voltage-dependent pore-blocking action
(Paoletti, Ascher et al. 1997), its allosteric inhibition through binding to the ATD is of particular
interest. Allosteric inhibition by zinc is subtype selective, exhibiting micromolar affinity for
GluN2B subunits but nanomolar affinity for GluN2A subunits, where zinc binding reduces
open channel probability (Paoletti, Ascher et al. 1997, Rachline, Perin-Dureau et al. 2005,
Amico-Ruvio, Murthy et al. 2011). Moreover, this inhibition occurs at physiologically relevant
zinc levels and/or during co-release of zinc with glutamate (Assaf and Chung 1984, Howell,
Welch et al. 1984). Modeling of the GluN2A ATD followed by functional studies of a GluN2Acontaining NMDA receptor showed that key negatively charged residues at the ‘entrance’ of
the ATD cleft are involved in screening zinc binding to the ATD (Paoletti, Perin-Dureau et al.
2000). Additionally, use of the substituted cysteine accessibility method (SCAM) within the
ATD cleft first suggested that the ATD cleft may be closing around a ligand, similar to the
LBDs or leucine/isoleucine/valine-binding proteins (LIVBPs) (Paoletti, Perin-Dureau et al.
2000). Mutagenesis of the GluN2A ATD and the structure of the zinc-bound GluN2B ATD
confirmed that zinc binds within the cleft of the bi-lobed structure of the ATD (Choi and Lipton
1999, Fayyazuddin, Villarroel et al. 2000, Karakas, Simorowski et al. 2009). Propping the ATD
cleft open using thiol-reactive crosslinking agents increases open channel probability,
suggesting that zinc binding to the ATD, proceeds through a cleft-closure mechanism (Gielen,
Retchless et al. 2009). Furthermore, molecular dynamics simulations support the premise that
the ATD of GluN2A can undergo a cleft closure type conformational change (Dutta,
Shrivastava et al. 2012). Taken together, these data provide indirect evidence that zinc inhibits
the NMDA receptor by closing the bi-lobed ATD and allosterically influencing the
conformational equilibrium between closed and open states. However, this change is not
observed in the structure of the zinc-bound ATD of GluN2B (Karakas, Simorowski et al. 2009),
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Figure 5.1: LRET on Soluble GluN2 ATDs. (A) LRET from the soluble GluN2A ATD is
shown and zinc causes a decrease in the lifetime (green curve) as compared to the apo
receptor (black curve). (B) LRET from the soluble GluN2B ATD, the black curve is the
apo and the green curve is with zinc.
and no structural data demonstrating this cleft-closure or measuring its extent have been
reported (Furukawa 2012). We employed LRET to detect these hypothesized zinc-induced
conformational changes in the isolated GluN2A or GluN2B ATD.
To characterize the conformational changes associated with zinc binding, we used the
soluble ATD protein, which had recently been crystallized and shown to have a functional zinc
binding site (Karakas, Simorowski et al. 2009). The soluble ATD of the GluN2B subunit was
monomeric up to a concentration of 5 mg/mL (~120 µM) (Karakas, Simorowski et al. 2009).
Soluble GluN2A and GluN2B ATDs were expressed in Hi5 cells using a baculovirus system.
These proteins had the secretion signal from the human placental alkaline phosphatase, so
that the media surrounding the cells contained the protein. Protein was concentrated and
purified using either a nickel column attached to an FPLC system or nickel beads. However,
complete purification was never achieved, due to a contaminating protein that seemed to copurify with the ATD and was in excess concentration of the ATD. For this reason, it was
necessary to include the thrombin recognition sequence and to quantify background due to
labeling of cysteines in contaminating proteins. The LRET lifetime was measured between the
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cysteine in the upper lobe of the ATD and the inherent cysteine in the lower lobe of the ATD
(Cys231 in GluN2A and Cys232 in GluN2B). Protein samples were labeled with terbium
chelate and Alexa555. Samples were excited at 337 nm and emission was detected at 565
nm. All measurements yielded a single exponential lifetime. In GluN2A, the apo lifetime was
275 µs (Figure 5.1), corresponding to a distance of 46 ± 0.6 Å (Table 5.1). The lifetime
decreased to 199 µs when the ATD was bound by zinc (Figure 5.1), corresponding to a
distance of 43 ± 0.3 Å (Table 5.1). The GluN2B lifetime for the apo ATD was 254 µs (Figure
5.1), a distance of 47 ± 0.6 Å. The lifetime similarly decreased when zinc was bound to the
ATD, giving a lifetime of 206 µs and a distance of 45 ± 0.6 Å. These data agree with the
Donor Lifetime
(µs)

Donor:Acceptor
Lifetime
(µs)

Distance
(Å)

GluN2A ATD

1649

275

46 ± 0.6

GluN2A ATD +
Zinc

1649

199

43 ± 0.3

GluN2B ATD

1417

254

47 ± 0.6

GluN2B ATD +
Zinc

1417

206

45 ± 0.6

Table 5.1: LRET lifetimes and Distances from Soluble ATDs. The error in the
distance was calculated by propagating the error in the fit of the LRET decay.
literature, which suggest that if propping open the ATD potentiates the receptor, then an
inhibitor must close the ATD conformation. Indeed, the binding of zinc results in a decrease
in the lifetime, corresponding to a decrease in the distance between the upper and lower lobes
of the ATD.
To ensure we were working with functional protein, we used Isothermal Titration
Calorimetry (ITC), as a functional assay. ITC measures the amount of energy it takes to
maintain the temperature of the chamber containing the protein, as a ligand is titrated in and
53

Figure 5.2: Isothermal titration calorimetry
characterizing the binding of zinc to the
isolated GluN2B ATD. The fit of the binding curve
yields a Kd of ~5 µM, similar to the published value
for the isolated GluN2B ATD (Karakas, Simorowski
et al. 2009, Tomitori, Suganami et al. 2012).
binds to the protein. A successful binding curve could not be established for the GluN2A ATD,
but a binding curve was established for GluN2B, and the Kd closely matched what was
presented in the literature (Figure 5.2). The fact that the protein was not pure resulted in a
much higher initial baseline (background) than expected or hoped for.
Because protein purification could not be achieved completely and functional studies
could not confirm we were working in a relevant system, other systems were sought. Fulllength receptors, though they come with their own challenges, are a better system because
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they reflect conformational changes in the context of a whole receptor, as would be found
physiologically. As such, these efforts at working with the soluble ATDs were abandoned, and
future studies focused on the full-length receptor.
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Chapter 6:
Tetrameric Arrangement of ATDs

This research was originally published in the Journal of Biological Chemistry. The text and figures have been
modified and reprinted with permission from Sirrieh, R.E., MacLean, D.M., Jayaraman, V. Amino-terminal
Domain Tetramer Organization and Structural Effects of Zinc Binding in the N-Methyl-d-aspartate (NMDA)
Receptor. Journal of Biological Chemistry. 2013; 288: 22555-64. © The American Society for Biochemistry
and Molecular Biology.
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6.1 Introduction
Before the crystal structure of the full NMDA receptor was solved, Karakas and
colleagues reported the structure of the isolated ATDs of a GluN1-GluN2B NMDA receptor in
a dimeric configuration (Karakas, Simorowski et al. 2011). This heterodimer structure was
unique among the structures of glutamate receptor ATDs because it showed a very close
interaction between the subunits and a novel possible arrangement because the ATDs
seemed to be almost perpendicular to each other. This novel arrangement prompted us to
study the conformational arrangement of the ATDs of the NMDA receptor in a full receptor.
Furthermore, in the AMPA receptor, the ATD layer is said to undergo a crossover, to where
the ATD of a subunit sits above the LBD of the adjacent subunits LBD. Due to a lack of a
structure, it was unknown whether a similar domain swap takes place in the NMDA receptor.
To address these questions, we used luminescence resonance energy transfer (LRET) to
map the tetramer organization in full-length, functional GluN1/GluN2A receptors.

6.2 Strategy for LRET measurements in CHO cells and X. laevis oocytes
To probe the orientation and distances between ATDs we measured three intersubunit distances, between the two GluN2A subunits, between GluN2A and GluN1 subunits,
and between the two GluN1 subunits. Receptors composed of GluN1 and GluN2A subunits
were co-expressed in CHO cells and X. laevis oocytes. All constructs used in the LRET
measurements were functional with zinc inhibition intact as determined using whole cell
current recordings in CHO cells (Figure 8.1).

6.3 Tetramer organization of GluN1/GluN2A ATDs
We measured the inter-subunit distance between GluN2A ATDs by co-expressing
GluN2A*C30 with GluN1*, and labeling with a donor: acceptor ratio of 1:1 (maleimide derivatives
of terbium chelate and Alexa555, respectively). Based on the LRET acceptor and donor only
lifetimes (Figures 6.1 and 6.2), the distances were calculated to be 44.2 ± 0.1 Å and 44.9 ±
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0.1 Å in CHO cells and oocytes, respectively (Table 6.1). The distances measured in standard
solutions which may contain trace amounts of zinc and in tricine buffered solutions which
contain no free zinc are identical, suggesting that any contaminating zinc is not significant
enough to influence the LRET measurements. These distances are substantially shorter than
any distances across analogous sites on the ATDs in the full length AMPA receptor (Figure
6.3).
To measure between the GluN1-GluN2A ATDs, GluN1*C30 was co-expressed with
GluN2A*H30. The LRET lifetimes for the distance between terbium chelate-labeled GluN1 and
Ni(NTA)2Cy3-labeled GluN2A subunits in CHO cells and oocyte membrane fractions are
shown in Figures 4 and 5. The lifetimes can be well represented by a single exponential decay,
suggesting we are measuring only a single distance. The distance is 50.6 ± 0.1 Å and 50.4 ±
0.1 Å in CHO cells and oocytes, respectively (Table 6.1). This distance is in good agreement
with the intra-dimer distance of 59 Å between ATD dimers in the full-length GluA2 AMPA
receptor structure.
Similar LRET measurements of GluN1-GluN1 inter-subunit distances in NMDA
receptors in CHO cells were made by expressing GluN1*C22 with GluN2A*H30. No LRET was
detectable when the construct was labeled with maleimide derivatives of terbium chelate and
Alexa 555 in both CHO cells and X. laevis oocytes (Figures 6.1 and 6.2). The lack of LRET
suggests that the inter-subunit distance between Cys22 on GluN1 subunits is >95 Å
(corresponding to energy transfer efficiencies of <0.1), consistent with the 97 Å distance in
the tetrameric crystal structure of isolated ATDs of the NMDA receptor (Figure 6.3). This
measurement does not rule out the configuration in the crystal structure of the full-length
AMPA receptor, which shows a distance of 127 Å for analogous sites. However, all three
distances taken together suggest that the ATDs in the NMDA receptor are indeed more
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compactly arranged (Karakas, Simorowski et al. 2011). The NMDA receptor ATDs do not
seem to be as splayed apart as the ATDs in the full length AMPA receptor structure.
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Figure 6.1: Lifetime measurements of NMDA receptor inter-subunit distances in
*
CHO cells. A) The GluN2A-GluN2A LRET lifetimes obtained by co-expressing GluN1 and
*C30
GluN2A
and labeling with terbium and Alexa 555 as donor and acceptor fluorophores,
respectively. B) The GluN1-GluN2A LRET lifetimes labeled with terbium and Ni(NTA)2Cy3
as donor and acceptor fluorophores, respectively. C) The GluN1-GluN1 LRET
measurements labeled with Terbium and Alexa 555 as donor and acceptor fluorophores,
respectively. D) Donor only lifetimes for the GluN2A-GluN2A measurements. E) The donor
only lifetimes for measurements between GluN1-GluN2A and GluN1-GluN1 are shown. In
all panels, the black line represents lifetimes from receptors in extracellular buffer, green
shows tricine-buffered solutions, blue illustrates solutions with saturating zinc, and pink
represents solutions with both saturating zinc and glutamate/glycine. All measurements
can be fit with a single exponential lifetime decay curve.

59

B
0.001

0.001

0.0001
*

GluN1 + GluN2A

*C30

250

500

0.0001

750

GluN1

*C22

+ GluN2A

250

Fluorescence intensity

Fluorescence intensity

0.001
*

GluN1 + GluN2A

500

*C30

1000

750

GluN1-GluN1 Measurement

0.002
0.001
0.000
-0.001
-0.002

GluN1

250

*C22

+ GluN2A

*H30

500

750

Time (µs)

Time (µs)

E

Donor Only Lifetime

*H30

500

Time (µs)

D

C

GluN1-GluN2A Measurement

Fluorescence Intensity

GluN2A-GluN2A Measurement

Fluorescence intensity

Fluorescence intensity

A

Donor Only Lifetime

Apo
Zinc
Zinc + Glu/Gly

0.1

GluN1

1500

*C22

+ GluN2A

500

Time (µs)

*H30

1000

1500

Time (µs)

Figure 6.2: Lifetime measurements of inter-subunit distances in NMDA receptors
expressed in X. laevis oocytes. A) GluN2A-GluN2A LRET lifetimes from co-expressed
*

*C30

GluN1 and GluN2A

labeled with terbium chelate and Alexa 555. B) The GluN1-GluN2A
*C22

LRET lifetimes measured from GluN1
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and GluN2A

when labeled with terbium chelate

and Ni(NTA)2Cy3. C) The GluN1-GluN1 LRET lifetimes obtained from GluN1
expressed with GluN2A
donor-labeled GluN2A
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and labeled with terbium chelate and Alexa 555. D) Lifetimes for

used to calculate GluN2-GluN2 distances. E) Donor only lifetimes
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labeled receptors to calculate GluN1-GluN2A and GluN1-GluN1 distances. In
all panels, the black line represents lifetimes from receptors in extracellular buffer, green
shows tricine-buffered solutions, blue illustrates solutions with saturating zinc, and pink
represents solutions with both saturating zinc and glutamate/glycine. All measurements can
be fit with a single exponential lifetime decay curve.
Similar measurements to those used to probe the tetramer organization were used to
characterize inter-subunit distances upon zinc binding and subsequent binding of the agonists
glutamate and glycine. The LRET lifetimes that probe the inter-subunit distances show no
change in the presence of zinc either alone or with saturating glutamate and glycine in both
CHO cells (Figure 6.1) and in oocytes (Figure 6.2). As such, the distances between subunits
in these ligated states are indistinguishable from the apo state (Table 6.1). Importantly, these
constructs all retain high affinity voltage independent zinc inhibition with IC50’s of 17 ± 2 and
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45 ± 2 nM for GluN1*C22/GluN2A*H30 and GluN1*/GluN2A*C30, respectively (Figure 8.2), in good
agreement with previously reported values for wild-type NMDA receptors composed of
GluN1/GluN2A subunits (Fayyazuddin, Villarroel et al. 2000, Zheng, Erreger et al. 2001,
Erreger and Traynelis 2005).

A

B

Figure 6.3 Top view of iGluR ATDs with measurements. Shown are the measurements
between the N-terminus of the ATDs of the GluA2 AMPA receptor (A). The measurements
are made at analogous sites to those measured between in the LRET experiments on the
NMDA receptor. Additionally, the subunits are labeled A-D according to the conformation
they adopt in the structure (See Chapter 1). (B) The tetramer measurements across the
ATDs of the GluN1-GluN2B NMDA receptor at analogous sites to those measured in the
LRET experiments.

6.4 Discussion
Our results corroborate that the tetramer organization of the NMDA receptor at the
ATD is quite distinct from that of the AMPA receptor. In the full length crystal structure, the
AMPA receptor subunits are organized as a dimer of dimers with the dimer pairs relatively far
apart from each other. This separation is evident in the distances measured between the αcarbons of the N-terminal residues of the ATD (Figure 6.3 A). The LRET yielded distances
that ranged from 45 Å to distances too great to be measured with LRET. The existence of
these shorter distances confirms that the ATDs are more compact in the NMDA receptor. The
recently solved structure of the GluN1-GluN2B NMDA receptor allows for comparison of our
measurements to the distances in the crystal structure. The GluN1-GluN2A distance
measured matches quite well to the distance within an ATD dimer (62 Å between α-carbons)
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in the GluN1-GluN2B structure (Figure 7.3 B). However, the other two distances, between
GluN2A ATDs and between GluN1 ATDs do not match. Several explanations could be offered
for this difference. First, the structure is of GluN1-GluN2B subunits, and our LRET
measurements were made in GluN1-GluN2A subunits, so the differences could reflect
differences in receptor assembly based on GluN2 subtype. Second, the crystal structure was
optimized by introducing crosslinks between the lower lobes of the GluN2B subunit (S214C
mutation) (Karakas and Furukawa 2014), so the angling of the upper lobes of the GluN2B
ATDs away from each other could be an artifact introduced by the construct used for
crystallization. The crosslink forms as confirmed by western blots (Karakas and Furukawa
2014), but the ATDs are thought to be very flexible, so although they could form that
conformation naturally, they may not occupy it as frequently as when they are held in place
by a crosslink. Finally, LRET measures the distance between the fluorophores, which have a
linker between the fluorescent moiety and the binding group. As such, the distances could
reflect the orientation of the probes in our system. Our data show definitively, however, that
the NMDA receptor ATDs are arranged more compactly than those of the AMPA receptor, as
later confirmed by the crystal structure. Additionally, the binding of zinc, an allosteric inhibitor,
does not cause any large-scale conformational changes at the upper lobes of the ATDs. The
addition of the agonists glutamate and glycine, which in these steady state measurements
means the desensitized state is being probed, similarly do not induce any large scale
movements in the upper lobes of the ATDs. These data suggest that the NMDA receptor
desensitizes differently from AMPA receptors, where the ATDs splay apart during
desensitization (Meyerson, Kumar et al. 2014).
Using atomic force microscopy, Suzuki and colleagues found that the height of the
NMDA receptor decreases approximately 1 nm when both agonists glutamate and glycine are
bound to the receptor (Suzuki, Goetze et al. 2013). The LRET data, on the other hand, shows
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no change in inter-subunit distances in the presence of glutamate and glycine, suggesting that
the upper lobes of the ATDs do not move apart during gating or desensitization. To integrate
these two observations, we speculate that LBD closure around the ligand results in
rearrangement of the LBD dimer interface (Borschel, Murthy et al. 2011) and a general
downward pulling on the ATDs, without altering the orientation of the ATD subunits at the top.
Essentially, the ‘shortening’ of the receptor upon agonist binding stems predominantly or
exclusively from closure motions of the LBD. Further experiments will be required to examine
the motions of the ATD-LBD linker during agonist and modulator binding.
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GluN2A-GluN2A LRET Lifetimes and Distances

CHO
Cells

X. laevis
oocytes

Ligated State (n)

Donor Only
Lifetime (µs)

Donor-Acceptor
Lifetime (µs)

Distance (Å)

Apo (3)

1554 ± 1.2

142 ±1.3

44.2 ± 0.1

Tricine buffered
(3)

1529 ± 1.4

149 ± 1.7

44.7 ± 0.1

Zinc (3)

1599 ± 1.2

147 ± 1.0

44.4 ± 0.1

Zinc, Glu/Gly (3)

1594 ± 1.3

145 ± 1.7

44.1 ± 0.1

Apo (3)

1528 ± 7.8

149 ± 2.2

44.9 ± 0.1

Zinc (3)

1631 ± 9.1

152 ± 1.6

44.5 ± 0.1

Zinc, Glu/Gly (3)

1578 ± 6.7

158 ± 2.4

45.1 ± 0.1

GluN1-GluN2A LRET Lifetimes and Distances
CHO
Cells

X. laevis
oocytes

Apo (5)

1502 ± 1.2

273 ± 3.3

50.6 ± 0.1

Tricine buffered
(2)

1497 ± 1.2

272 ± 2.8

50.6 ± 0.1

Zinc (2)

1549 ± 1.2

295 ± 5.7

51.1 ± 0.2

Zinc, Glu/Gly (3)

1563 ± 1.3

302 ± 4.4

51.0 ± 0.1

Apo (6)

1725 ± 1.4

308 ± 3.3

50.4 ± 0.1

Zinc (3)

1700 ± 1.3

298 ± 4.0

50.2 ± 0.1

Zinc, Glu/Gly (3)

1710 ± 1.4

299 ± 3.6

50.2 ± 0.1

GluN1-GluN1 LRET Lifetimes and Distances
CHO
Cells

X. laevis
oocytes

Apo (3)

1502 ± 1.2

no LRET

> 95

Tricine buffered
(1)

1497 ± 1.2

no LRET

> 95

Zinc (3)

1549 ± 1.2

no LRET

> 95

Zinc, Glu/Gly (3)

1563 ± 1.3

no LRET

> 95

Apo (3)

1725 ± 1.4

no LRET

> 95

Zinc (3)

1700 ± 1.3

no LRET

> 95

Zinc, Glu/Gly (3)

1710 ± 1.4

no LRET

> 95
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Table 6.1: Inter-subunit LRET lifetimes and distances. Shown are the lifetimes and
corresponding distances for the measurements between the upper lobes of the ATDs in a
GluN1-GluN2A receptor. There were no changes in the distances when the receptor was
bound by zinc or zinc and the agonists glutamate and glycine.
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Chapter 7:
Electrostatics and Subtype-dependent
ATD Conformations

Some of the research presented here was originally published in the Journal of Biological Chemistry. The
text and figures have been modified and reprinted with permission from Sirrieh, R.E., MacLean, D.M.,
Jayaraman, V. Amino-terminal Domain Tetramer Organization and Structural Effects of Zinc Binding in the
N-Methyl-d-aspartate (NMDA) Receptor. Journal of Biological Chemistry. 2013; 288: 22555-64. © The
American Society for Biochemistry and Molecular Biology.
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7.1 Electrostatics of Isolated GluN2A and GluN2B ATDs
Electrostatics likely influence modulator activity, especially when dealing with
charged modulators such as zinc, ifenprodil, and spermine. Surface electrostatics of
the isolated GluN2A and GluN2B were calculated (described in 4.8) using the APBS
plugin on VMD. The GluN2A ATD primary sequence was modeled on the crystal
structure of the GluN2B ATD, because the structure of the GluN2A ATD has not yet
been solved. When comparing the electrostatics of the apo ATDs, one can clearly see
that at the zinc binding site (white arrows in Figure 7.1), there is a red (negative) patch
around the binding site. It is also evident that the size of the electronegative patch is
larger in GluN2A than in GluN2B. This difference could help account for the difference
in zinc affinity for the GluN2 ATDs. The zinc is more easily attracted to the GluN2A
ATD, and the greater number of residues available to coordinate the zinc create a
high-affinity binding site. In GluN2B, there is less of an electronegative patch, and less
residues available to coordinate the zinc, creating an intermediate affinity zinc binding
site.
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A

B

GluN2A ATD

GluN2B ATD

Figure 7.1: Electrostatics of GluN2 ATDs. (A) Electrostatics of the GluN2A ATD,
generated by modeling the primary sequence of the GluN2A ATD on the GluN2B ATD
crystal structure. There is clearly a red, electronegative patch around the zinc binding
site, which is larger than the negative area around the GluN2B zinc binding site (B).
Cyan colored residues in the red patches are the zinc binding residues.

In fact, when comparing the electrostatics in the zinc-bound and apo GluN2B
ATDs, it is clear that the binding of the zinc cation induces a greater negative charge
in the surface of the protein (Figure 7.2). These figures only show the surface of the
protein. If the positively charged modulator were included, we would expect, rather, to
see a neutral patch at that position.
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A

B

Figure 7.2: Electrostatics of GluN2B ATD with and without zinc. Shown in (A) is
the apo GluN2B ATD, and in panel (B) one can clearly see the greater negative (red)
patch surrounding the zinc binding site. Highlighted in cyan are the zinc binding
residues.

Additionally, as mentioned above, ifenprodil is positively charged, and the
binding of ifenprodil at the interface similarly induces an increase in the negative
charges upon binding (Figure 7.3). The differences in electrostatics, again, could be
influencing the affinity to the modulator.
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A

B

Figure 7.3: Ifenprodil-induced changes in Electrostatics. The
interface of the apo GluN2B ATD (A) acquires a more negative
surface upon binding of ifenprodil at the surface (B). The green
residue highlighted in the lower lobe of the ATDs is Glu211 and
serves as a reference point for comparison between the two
structures.

7.2 Subtype dependent conformations of the ATD
In addition to differences in the electrostatics, studies have shown that the ATDs
dictate Po, and suggested that the conformation of the ATD is what influences Po. In order to
directly characterize the differences in the ATDs, we performed LRET and labeled at identical
sites in the GluN2A and GluN2B ATDs, with identical fluorophores, and the same buffer
system to allow for an easier comparison of the distances measured.
First, the conformational state of the GluN2B ATD was probed by co-expressing the
GluN2Bcleft construct with a cys-free GluN1 (the GluN1* construct). The GluN2Bcleft allows for
the inherent cysteine in the lower lobe of the GluN2B at site 232, to be labeled with the donor
fluorophore and the N-terminus of the ATD, in the upper lobe, to be labeled with the acceptor
fluorophore via a hexa-His tag. The specific introduction of donor and acceptor fluorophores
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on the ATD and the introduction of the thrombin cleavage site between the two allowed for
isolation of an LRET signal specifically within the labeled ATD of the NMDA receptor
expressed in the cells, without a confounding signal across the subunits. The LRET lifetime
was determined by measuring the lifetime of sensitized acceptor emission upon donor
excitation. The LRET lifetime after background fluorescence subtraction (achieved by
thrombin cleavage of the NMDA receptor) is shown in Figure 7.4. The lifetime from the
receptor in the apo state could be well represented by a single exponential with a lifetime of
252 ± 12 µs, which corresponds to a distance of 48.8 ± 0.4 Å between the two fluorophores
(Table 7.1). The single lifetime suggests that the measurements correspond to distances
within the subunit, as expected based on the crystal structures, where there is no cross talk
across the subunits for these sites. The same sites had been used to measure across the
GluN2A ATD cleft, a hexa-his tag after residue 30 and the inherent cysteine (residue 231 in
GluN2A), and the same fluorophores were used to label at these sites (Sirrieh, MacLean et
al. 2013). The LRET lifetime measured between these sites in GluN2A was 312 ± 5.4 µs
(Figure 7.4), corresponding to a distance of 51.2 ± 0.1 Å (Table 7.1) (Sirrieh, MacLean et al.
2013). These measurements show that the GluN2B cleft is inherently in a more closed
conformation than the GluN2A cleft.
Additionally, manipulation of the GluN1 ATD modulates Po of the receptor (Zhu,
Stroebel et al. 2013). To determine what the GluN1 ATD conformation was, we co-expressed
the GluN1cleft construct with either a cys-free GluN2A (GluN2A*) or GluN2B (GluN2B*). The
results surprisingly showed that the GluN1 ATD assumes different conformations when coassembled with different GluN2 subunits. When co-assembled with GluN2A, the LRET lifetime
was 324 ± 13 µs, corresponding to a distance of 51.2 ± 0.3 Å. When co-assembled with
GluN2B, the LRET lifetime was 275 ± 3.5 µs, a distance of 49.2 ± 0.1 Å. These data suggest
three things. First, the GluN1 ATD adopts a more open conformation when co-assembled with
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GluN2A. Second, the GluN1 ATD may be involved in dictating the Po of the receptor in
combination with the GluN2 ATD. These receptors have a higher Po than GluN1/GluN2B
receptors, and GluN1 is in an inherently more closed conformation when co-assembled with
GluN2B. Third, the difference in the conformation suggests that the GluN1-GluN2 ATD
interface differs when the receptor is composed of GluN2A or GluN2B. Differences in the
interface were thought to arise from differences in the primary sequence and conformation of
the GluN2 ATD. Since the GluN1 ATD is in a different conformation with different partners,
there are likely different residues contributed to the ATD interface.
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Figure 7.4: The different conformations adopted by apo ATDs. (A) Shown is the
crystal structure of the GluN2B ATD (PDB ID 3JPW) in the zinc free state. Highlighted
in purple and magenta are the inherent cysteine in the lower lobe of the ATD (conserved
in GluN2A – Cys231) and the location of the insertion of the hexa-his tag at the Nterminus, which is again the same site used in GluN2A cleft measurements. (B) The
LRET lifetimes of the apo GluN2B cleft (black) and the tricine-buffered GluN2A cleft
(green) are shown. (C) The crystal structure of the GluN1 ATD (PDB ID 3Q41) is shown
highlighting residues that were mutated to cysteines to accept fluorophores. (D) The
LRET lifetimes from the GluN1 ATD vary when GluN1 is co-expressed with GluN2A or
GluN2B.
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Ligated State (n)

Donor Only
Lifetime (µs)

Donor-Acceptor
Lifetime (µs)

Distance (Å)

GluN2B Cleft – GluN1* + GluN2B*cleft (Ni(NTA)2Cy3)
Apo (3)

1649 ± 1

204 ± 1.3

48.8 ± 0.4

GluN2A Cleft – GluN1* + GluN2A cleft (Ni(NTA)2Cy3)
Apo (2)

1590 ± 1.3

312 ± 5.4

51.2 ± 0.1

275 ± 4

49.2 ± 0.1

324 ± 13

51.2 ± 0.3

GluN1 Cleft – GluN1*cleft + GluN2B*(Alexa555)
Apo (2)

1740 ± 1

GluN1 Cleft – GluN1*cleft + GluN2A*(Alexa555)
Apo (2)

1685 ± 1

Table 7.1: LRET lifetimes and distances for Apo ATDs. The error in the lifetimes is the
SEM.
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Chapter 8:
Zinc Induces a Cleft-Closure
Conformational Change

This research was originally published in the Journal of Biological Chemistry. Sirrieh,
R.E., MacLean, D.M., Jayaraman, V. Amino-terminal Domain Tetramer Organization
and Structural Effects of Zinc Binding in the N-Methyl-d-aspartate (NMDA) Receptor.
Journal of Biological Chemistry. 2013; 288: 22555-64. © The American Society for
Biochemistry and Molecular Biology.
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8.1 Zinc Induced Conformational Changes
To study the conformational changes within the ATD of GluN2A subunits upon binding
zinc, LRET lifetimes were obtained using the GluN2Acleft construct, which retains Cys231,

A

zinc

glutamate

Control

3 nM
30 nM
300 nM

0.5 nA
2 sec

B
Relative response

1.0

GluN1* /GluN2A*C30

0.9

GluN1*C22/GluN2A*H30
GluN1* /GluN2A*H30 + C231
GluN1* /GluN2A*H30 + C231/DHM

0.8

0.7

0

-9

10

10-8

10-7

10-6

10-5

[Zinc] (M)
Figure 8.1: Zinc sensitivity of constructs used for LRET. (A)
Representative whole cell recording from CHO cell expressing
GluN1*/GluN2A*H30+C231 receptors in response to 100 µM
glutamate alone or with 3, 30 or 300 nM free zinc. (B) Summary
zinc inhibition curves for each construct recorded at +50 mV with
4-8 cells for each point. Note that each construct shows high
affinity zinc block with an IC50 between 17 and 45 nM zinc, except
for the zinc-insensitive GluN2A*H30+C231/DHM mutant (red circles).
Electrophysiology performed by Dr. David MacLean.
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located in the lower lobe of the ATD. The receptor composed of GluN1*/GluN2Acleft retains
high affinity zinc inhibition with an IC50 of 35 ± 2 nM (Figure 8.1), which is consistent with
previously reported wild-type affinities (Fayyazuddin, Villarroel et al. 2000, Zheng, Erreger et
al. 2001, Erreger and Traynelis 2005). GluN2Acleft was co-expressed with GluN1* in CHO cells,
and receptors were labeled with a maleimide derivative of terbium chelate, which binds to
Cys231 and a Ni-NTA conjugate of Cy3, which binds the hexa-His tag. This labeling strategy
eliminated energy transfer between the N-termini of GluN2A subunits within the tetramer,
allowing us to directly measure the GluN2A ATD cleft. The sensitized acceptor and donor only
lifetime measurements (Figure 8.2) yield a distance of 51.6 ± 0.2 Å and 51.2 ± 0.1 Å in CHO
cells using standard solutions or tricine buffered solutions, respectively (Table 2). Zinc binding
induced a 3.5-4 Å decrease in distance between the donor and acceptor sites relative to the
unligated states, with the distance being 47.7 ± 0.1 Å (Figure 8.2 and Table 8.1). This result
suggests a cleft-closure conformational change takes place in the ATD upon zinc binding.
Subsequent binding of the agonists glutamate and glycine does not alter the intra-subunit
distance of the GluN2A ATD cleft (Figure 8.2). These measurements were completed to
determine if binding of the agonists to the LBD altered the conformation of the ATD because,
as discussed in Chapter 2, zinc and glutamate binding is cooperative. The cooperativity
suggests that the conformation may be altered at the ATD by agonist binding. In our ensemble
measurements, however, no differences were detected when the agonists were bound.
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Figure 8.2: LRET lifetime measurements of the GluN2A ATD cleft. A) The LRET
lifetimes measured across the intra-subunit ATD cleft of GluN2A, obtained by coexpressing GluN1* and GluN2A*clft and labeling with terbium chelate and Ni(NTA)2Cy3.
B) The same lifetime measurement as in A) performed on a zinc-insensitive GluN2A
with mutations H44A and H128S. This measurement was obtained by co-expressing
GluN1* and GluN2A*DHM and labeling with terbium chelate and Ni(NTA)2Cy3. C) and D)
Donor only lifetimes for the cleft measurements from constructs in panels A) and B),
respectively. In all panels, the black line represents lifetimes from receptors in
extracellular buffer, green shows tricine-buffered solutions, blue illustrates solutions with
saturating zinc, and pink represents solutions with both saturating zinc and
glutamate/glycine.
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Wild Type Zinc Binding
Constructs: GluN1* + GluN2A*cleft
DonorDonor Only
Ligated State (n)
Acceptor
Lifetime (µs)
Lifetime (µs)

Distance (Å)

Apo (4-6)

1546 ± 1.4

316 ± 8.1

51.6 ± 0.2

Tricine buffered
(2)

1590 ± 1.3

312 ± 5.4

51.2 ± 0.1

Zinc (4)

1592 ± 1.3

219 ± 3.4

47.7 ± 0.1

Zinc, Glu/Gly (1)

1610 ± 1.4

211 ± 1.6

47.4 ± 0.1

Zinc Insensitive Mutant
Constructs: GluN1* + GluN2A*DHM
Apo (4-6)

1539 ± 2.0

302 ± 2.8

51.4 ± 0.1

Tricine buffered
(2)

1547 ± 2.7

304 ± 3.2

51.4 ± 0.1

Zinc (4)

1591 ± 3.1

313 ± 5.5

51.4 ± 0.2

Table 8.1: Lifetimes and distances from LRET measurements. In
parentheses after the ligated state for each construct is the n value. The
error in the LRET lifetime is the SEM, and the error in the distances was
calculated by propagating the errors in the lifetimes.
In order to confirm that the cleft-closure was caused by zinc binding to the ATD, we
combined two mutations in the ATD (H44A and H128S) which individually reduce zinc
inhibition (Choi and Lipton 1999, Fayyazuddin, Villarroel et al. 2000) onto the background of
our GluN2Acleft construct used for cleft-closure measurements, called GluN2ADHM.
Electrophysiology experiments confirm that this construct shows no substantial voltageindependent inhibition by zinc at concentrations as high as 10 µM (Figure 8.1). These
experiments reveal that the cleft-closure is zinc dependent because acceptor and donor only
lifetimes of receptors in the apo state, receptors in tricine-buffered solutions, and receptors in
zinc-added solutions all yielded distances that were identical, 51.4 ± 0.1 Å (Figure 8.2 and
Table 8.1). The distance matches the cleft distance in the apo receptor with wild type zinc
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binding (Table 8.1). These experiments demonstrate that zinc induces a cleft-closure
conformational change in the bi-lobed ATD structure of GluN2A.
GluN1-GluN2 interactions may also play a role in zinc modulation. Recent work by Zhu
and colleagues argue that the GluN1 ATD undergoes both twisting and cleft-closure
conformational changes as well as interacting with the GluN2B ATD to influence glutamate
binding at the LBD (Zhu, Stroebel et al. 2013). However, any such interactions would arise
without causing large scale motions between the upper lobes in intact functional receptors
(Figures 6.1 and 6.2). These findings and recent computational studies suggest that the NTDs
of both GluN1 (Zhu, Stroebel et al. 2013) and GluN2B undergo lateral twisting motions
(Burger, Yuan et al. 2012, Dutta, Shrivastava et al. 2012) as well as cleft-closure movements
(Dutta, Shrivastava et al. 2012, Zhu, Stroebel et al. 2013).
To map potential twisting motions in the lower lobe of the GluN2A ATD, the inherent
Cys231 in GluN2A was maintained in a cys-free background (GluN2A*C231) and co-expressed
with GluN1*C22 to measure between the lower lobe of GluN2A and the upper lobe of GluN1.
The receptor was labeled with terbium chelate and Alexa555. The lifetime from the apo
receptor was 187 ± 5.6 µs (Figure 8.3), a distance of 45.9 ± 0.2 Å (Table 8.2), and the lifetime
decreased to 156 ± 8.7 µs (Figure 8.3), a distance of 44.4 ± 0.4 Å when zinc was bound (Table
8.2). On average, the distance between these two sites decreased by ~2 Å. A second
measurement was made between GluN2A Glu211Cys (GluN2A*211), which is on the adjacent
helix to Cys231, and the upper lobe of GluN1 (co-express with GluN1*C22). Receptors were
labeled with terbium chelate and Fluorescein. The LRET lifetimes again decreased when zinc
was bound (Figure 8.3 and Table 8.2), corresponding to ~2 Å decrease in the distance
between these two sites. Given that both of these distances decreased, and the GluN2A ATD
closed around the zinc, the best explanation we can propose is that the lower lobe of the
GluN2A ATD does indeed rotate towards the upper lobe of the GluN1 ATD.
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Figure 8.3: Zinc induces a rotational movement in the GluN2A ATD. (A) LRET
measurements from the upper lobe of GluN1 to the lower lobe of GluN2A (Glu211Cys) are
shown. The apo curve is in green and the zinc-bound receptor is in blue. (B) The LRET
lifetimes from the measurement between the upper lobe of GluN1 to the lower lobe of
GluN2A (Cys231) are shown with the apo receptor in green and the zinc-bound receptor
in blue.
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Ligated State (n)

Donor Only
Lifetime (µs)

Donor-Acceptor
Lifetime (µs)

Distance (Å)

GluN1*C22 + GluN2A*C231 (Alexa555)
Apo (3)

1692 ± 0.9

187 ± 5.6

45.9 ± 0.2

Zinc (2)

1683 ± 0.8

156 ± 8.7

44.4 ± 0.4

GluN1*C22 + GluN2A*211 (Fluorescein)
Apo (2)

1710 ± 0.9

239 ± 1.3

33.2 ± 0.1

Zinc (2)

1702 ± 0.9

176 ± 1.4

31.4 ± 0.1

Table 8.2 LRET Lifetimes and Distances of GluN2A twisting. The lifetimes and
distances measuring between the lower lobe of GluN2A and the upper lobe of GluN1.

8.2 Discussion
NMDA receptors differ from the AMPA and kainate receptor subtypes in their ability to
bind small molecule allosteric inhibitors at their ATD. Crosslinking and cleft-locking
experiments provide indirect evidence for a cleft-closure conformational change induced by
these small molecules (Gielen, Le Goff et al. 2008, Gielen, Retchless et al. 2009). However,
the crystal structures of the isolated GluN2B ATD in the apo and zinc-bound forms (PDB IDs
3JPW and 3JPY) are both in the closed cleft conformation, with only a 0.3 Å difference
between the α-carbons of residues labeled in our experiments (Figure 2.1) (Karakas,
Simorowski et al. 2009). The LRET data presented here shows that on average the GluN2A
ATD cleft is more closed in the zinc bound state relative to the cleft in the absence of zinc.
This is further confirmed by the absence of this change in the zinc-insensitive mutant (Figure
8.2).
In both the absence and presence of zinc, crystal structures capture a closed-cleft
state of the ATD, suggesting that this domain samples a range of conformations from an open
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to a closed cleft state (Figure 2.1) (Karakas, Simorowski et al. 2009). A similar situation occurs
with the LBD of AMPA receptors where single molecule FRET (smFRET) studies show that
the LBD samples a spectrum of open and closed cleft conformations in both apo and agonistbound states (Landes, Rambhadran et al. 2011, Ramaswamy, Cooper et al. 2012), with the
agonist bound forms on average being more closed. Similar NMR and smFRET studies such
as those performed on the AMPA receptor LBD may be able to provide insight into the role of
such dynamics in zinc modulation of the receptor function (Maltsev, Ahmed et al. 2008,
Maltsev and Oswald 2010, Landes, Rambhadran et al. 2011, Ramaswamy, Cooper et al.
2012).
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Chapter 9:
Cleft Closure is a Common Mechanism of
Inhibition: Cue Ifenprodil

This research has been submitted for consideration for publication to the Journal of
General Physiology. Sirrieh, R.E., MacLean, D.M., Jayaraman, V. “A conserved
structural mechanism of NMDA receptor inhibition: a comparison of ifenprodil and
zinc.”
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9.1 Mechanism of Ifenprodil Inhibition
Zinc inhibits the NMDA receptor by stabilizing a closed GluN2 ATD cleft (Gielen, Le
Goff et al. 2008, Sirrieh, MacLean et al. 2013). To determine if the GluN2B specific inhibitor
ifenprodil, which binds at the interface between the GluN1 and GluN2B ATDs (Figure 1.4),
induces a cleft closure in the GluN2B ATD similarly to zinc, we used LRET to monitor the
conformational state of the GluN2B ATD. The same inherent cysteine in the lower lobe of the
GluN2 ATD as used for the zinc measurements and a hexa-histidine tag at the N-terminus of
the ATD (Sirrieh, MacLean et al. 2013) were labeled with terbium chelate and Ni(NTA)2Cy3,
as the donor and acceptor fluorophores, respectively. The lifetime from the apo receptor was
252 ± 12 µs, which is a distance of 48.8 ± 0.4 Å between the two fluorophores. Upon ifenprodil
binding, the lifetime decreases to 227 ± 26 µs, a distance of 47.0 ± 0.9 Å, about 2 Å of cleft
closure. Importantly, the receptors encoded by these mutants were inhibited by 10 µM
ifenprodil to the same degree, 81.6 ± 2.7 % inhibition in wild type receptors and 81.7 ± 2.9 %
inhibition for the GluN2Bcleft-GluN1* receptor (Figure 9.2).
Since the GluN1 ATD adopts different conformations when co-assembled with
different GluN2 subunits, we knew that it was able to undergo conformational changes. We
wanted to determine if ifenprodil, which binds at the interface between GluN1 and GluN2B
affects the conformation of the GluN1 ATD. We used LRET to measure the distances between
the upper and lower lobes of the GluN1 ATD in the presence of ifenprodil. The distance of the
GluN1 cleft for the apo receptor 49.2 Å (Figure 9.1, Table 9.1, Chapter 7). The lifetime for the
ifenprodil-bound receptor was 263 ± 1.5 µs (Figure 9.1), corresponding to an almost identical
distance of 48.7 ± 0.1 Å. Ifenprodil does not affect the overall conformation of the GluN1 ATD.
The receptor was 79.6 ± 2.7% inhibited by ifenprodil, similar to the wild type receptor (Figure
9.2).
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Figure 9.1: Ifenprodil’s effects on ATD cleft Conformations. (A) LRET measurements in
the GluN2B cleft reveal that ifenprodil induces a cleft-closure. (B) LRET measurements of
the GluN1 cleft. Shown in panels (C) and (D) are the donor only lifeteims for the GLuN2B
and GluN1 clefts, respectively. In all panels, the black curve is from the apo receptor and the
maroon curve is from the ifenprodil bound receptor.
Although zinc induced no change in the GluN1-GluN2A distance, we wanted to confirm
that this stability at the upper lobes extended to modulators which bind at the ATD interface.
To measure the distance between the upper lobes of the GluN1 and GluN2B ATDs, we coexpressed the GluN1*C22 construct with GluN2B*H30 and labeled the receptor with terbium
chelate and Ni(NTA)2Cy3. The LRET lifetime for the apo receptor was 362 ± 26 µs (Figure
9.3), a distance of 52.1 ± 0.6 Å. The lifetime when the receptor was bound by ifenprodil was
347 ± 26 µs (Figure 9.3), corresponding to a similar distance of 52.0 ± 0.6 Å (Table 9.1).
Although the distances between the upper lobes of the ATDs does not change at the
sites we measured, this data does not preclude the possibility that the GluN1 and GluN2B
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Figure 9.2: Ifenprodil Inhibition Electrophysiology.
(A) A sample whole-cell recording showing ifenprodil
inhibition of NMDA receptors. (B) The extent of ifenprodil
inhibition is plotted in comparison to the wild type
receptor. Electrophysiology was performed by Dr. David
MacLean.
ATDs are forming new contacts during modulation. In fact, crosslinking studies between the
two ATDs suggest that mobility is required and that the two subunits may indeed be interacting
(Karakas, Simorowski et al. 2011). If the upper lobes of the ATDs are not moving with respect
to each other, but there are conformational changes taking place within an ATD, the data
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suggests the lower lobes of the ATDs are moving. Zinc was found to induce a rotational
movement in the lower lobe of the GluN2A ATD, so that it moves closer to the upper lobe of
the GluN1 ATD. To map the movement of the lower lobe of the GluN2B ATD, which seems to
close when ifenprodil binds, we measured the LRET between the lower lobe of the GluN2B
ATD and the upper lobe of the GluN1 ATD. First, we co-expressed the GluN1*C22 with
GluN2B*232 and labeled the receptor with terbium chelate and Alexa555. The sensitized
acceptor lifetime of the apo receptor was 229 ± 9 µs (Figure 9.4), giving a distance of 47.8 ±
0.4 Å (Table 9.1). The lifetime decreased to 194 ± 8 µs when the receptor was bound by
ifenprodil, corresponding to 46.2 ± 0.3 Å. Ifenprodil inhibition is normally maintained with 74.6
± 2.9 % inhibition at saturating concentrations of ifenprodil (Figure 9.2). Additionally, zinc
induces a decrease in this distance between the upper and lower lobes of the GluN2B ATD
(Figure 9.3 and Table 9.1). Second, we will measure between a second set of sites by coexpressing the GluN1*CT with GluN2B*210 constructs and labeling the receptor with terbium
chelate and fluorescein. This construct has already been functionally characterized and is
normally inhibited by ifenprodil, 74.8 ± 3.3 % inhibition. When ifenprodil binds, the cleft closes,
but the lower lobe also twists towards the upper lobe of the GluN1 ATD as demonstrated by
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Figure 9.3: Inter-subunit measurements with Ifenprodil. Shown in panel (A) is the
LRET measurement between the upper lobes of the GluN1 and GluN2B ATDs. In black is
the apo receptor and in maroon is the ifenprodil-bound receptor. (B) Donor only lifetimes
for the GluN1-GluN2B upper lobes measurements.
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the decrease in both of the measurements made between the lower lobe of the GluN2B ATD
and the upper lobe of the GluN1 ATD.
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Figure 9.4: LRET measurements showing twist of GluN2B ATD. (A) Changes in the
LRET lifetime induced by ifenprodil. In black is the LRET lifetime from the apo receptor and
in maroon is the lifetime with ifenprodil. (B) Zinc similarly induces a reduction in the LRET
lifetime. In black is the LRET lifetime from the apo receptor, and the zinc-bound receptor
is in green. (C) The donor only lifetimes from the apo (black), ifenprodil-bound (maroon),
and zinc-bound (green) receptors.
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Ligated State (n)

Donor Only
Lifetime (µs)

Donor-Acceptor
Lifetime (µs)

Distance (Å)

GluN2B Cleft – GluN1* + GluN2B*cleft (Ni(NTA)2Cy3)
Apo (3)

1847 ± 1

252 ± 12

48.8 ± 0.4

Ifenprodil (4)

1826 ± 1

227 ± 26

47.0 ± 0.9

GluN1 Cleft – GluN1*cleft + GluN2B*(Alexa555)
Apo (2)

1740 ± 1

275 ± 4

49.2 ± 0.1

Ifenprodil (2)

1747 ± 1

263 ± 1.5

48.7 ± 0.1

GluN1-GluN2B Upper Lobes – GluN1*CT + GluN2B*HT(Ni(NTA)2Cy3)
Apo (5)

1738 ± 1

362 ± 26

52.1 ± 0.6

Ifenprodil (2)

1807 ± 1

374 ± 26

52.0 ± 0.6

GluN1 Upper Lobe-GluN2B Lower Lobe – GluN1*CT + GluN2B*232 (Alexa555)
Apo (3)

1674 ± 16

228 ± 9

47.8 ± 0.3

Ifenprodil (3)

1694 ± 3.5

194 ± 8

46.2 ± 0.3

1727 ± 1

184 ± 4

45.6 ± 0.2

Zinc (3)

Table 9.1: Ifenprodil LRET lifetimes and Distances. Shown are the lifetimes and
distances from measurements in GluN1/GluN2B receptors in the apo, ifenprodil bound,
and zinc bound states.

9.2 Discussion
Ifenprodil induces similar conformational changes upon binding to GluN1-GluN2B
receptors as zinc does upon binding to GluN1-GluN2A receptors. The GluN2 domain closes
upon binding of the inhibitor, and the lower lobe of the GluN2 ATD moves towards the upper
lobe of the GluN1 ATD in a rotational movement. The GluN1 ATD conformation is unaffected
by the binding of either zinc or ifenprodil. Interestingly, ifenprodil induces a much smaller
conformational change than does zinc. We suggest that the lesser degree of conformational
change stems from the inherently more closed ATD of the GluN2B subtype relative to the
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GluN2A subtype. Ifenprodil pushes the GluN2B ATD towards the limit of domain closure as a
mechanism to achieve inhibition, and it has less to close the domain than an inhibitor of the
GluN2A subtype. Interestingly, the distance between the upper lobes of the GluN1 and
GluN2B subunits, within an ATD dimer, are almost identical (~51 Å) to the distance between
the upper lobes of GluN1 and GluN2A subunits. This similarity suggests that the lower lobes
of the ATDs are oriented differently in GluN2A and GluN2B subunits.
Ideally, we would have liked to complete measurements of the GluN2B cleft and the
GluN1-2B distance at the upper lobes of the ATDs with zinc, to be able to draw a complete
comparison between zinc and ifenprodil inhibition. However, the higher concentration of zinc
required to saturate GluN2B containing receptors caused a displacement of the terbium from
the chelate or the Ni(NTA)2Cy3 from the hexa-his tag, making it impossible to subtract
background and accurately measure the lifetime.
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Chapter 10:
Spermine potentiates via a reverse inhibition
structural mechanism

This research was originally published in the Journal of Biological Chemistry. Sirrieh,
R.E., MacLean, D.M., Jayaraman, V. Subtype dependent NMDA receptor aminoterminal domain conformations and modulation by spermine. Journal of Biological
Chemistry. 2015; 290: 12812-20. © The American Society for Biochemistry and
Molecular Biology.
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10.1 Spermine Induced Conformational Changes
To determine the effect of spermine binding, the LRET lifetime was again measured
across the GluN2B cleft (using the GluN2Bcleft construct co-expressed with GluN1*) in the
presence of the GluN2B specific potentiator spermine. The LRET lifetime increases to 369 ±
34 µs (Figure 10.1), corresponding to a distance of 52.8 ± 0.8 Å (Table 10.1). The increase in
the distance upon addition of spermine is consistent with an opening of the cleft of the GluN2B
ATD. Importantly, this construct was potentiated by spermine to the same extent as the wildtype receptor (K., Zappia et al. 1994, Mony, Zhu et al. 2011), with equilibrium responses
increasing by 1.66 ± 0.10 (n=3) fold and 1.41 ± 0.05 (n=5) fold, respectively, in the presence
of spermine (Figure 10.2). Spermine binding stabilizes an open conformation of the GluN2B
ATD, and, since spermine likely binds at the interface between the GluN1 and GluN2B ATDs,
the conformation of the GluN1 ATD can be influenced by spermine binding.
It has been shown that the GluN1 ATD is necessary to the mechanism of allosteric
modulation as its deletion or cleavage affects allosteric inhibition and potentiation (Madry,
Mesic et al. 2007, Mony, Zhu et al. 2011). The structural role of the GluN1 ATD in spermine
modulation, however, is unclear, aside from potentially contributing amino acids to the
spermine binding site (Mony, Zhu et al. 2011, Tomitori, Suganami et al. 2012). The GluN1
ATD can be passive, simply acting as a wedge that supports the GluN2 ATD so that
conformational changes in the GluN2 ATD can be efficiently propagated to the LBDs and the
pore. Alternatively, the GluN1 ATD can be directly influenced and undergo conformational
changes upon binding of the modulator, particularly a modulator like spermine which likely
binds at the interface between the GluN1 and GluN2B ATDs. To determine the role of the
GluN1 ATD in spermine potentiation, we measured conformational changes in the GluN1 cleft
by introducing two cysteines, one each in the upper and lower lobes of the ATD. These
cysteines, the inherent one at position 22 and the second introduced by the Ser224Cys
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Figure 10.1: Spermine stabilizes an open cleft of both GluN1 and GluN2B ATDs.
LRET measurements of the GluN2B (A) and GluN1 (B) clefts are shown. In (C) and (D)
are the donor only measurements for the GluN2B and GluN1 subunits, respectively. In
all panels, the black curve is from the apo receptor and the blue curve is from the
spermine-bound receptor.
mutation in the GluN1 ATD, would allow for direct monitoring across the cleft of the bi-lobed
ATD. This GluN1cleft construct was co-expressed with a cys-free GluN2B (GluN2B*). The
LRET lifetime of the GluN1 cleft for the apo receptor could be well represented with a single
exponential decay corresponding to 275 ± 4 µs (Figure 10.1), giving a distance of 49.2 ± 0.1
Å (Table 10.1). Again, based on the crystal structure this distance is consistent with the
measurement being within a single ATD and not across the subunits. Additionally, this
construct was normally potentiated with equilibrium responses increasing by 1.79 ± 0.07 (n=9)
fold in the presence of spermine (Figure 10.2). Addition of spermine led to an increase in the
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LRET lifetime to 340 ± 29 µs (Figure 10.1), corresponding to a distance of 51.5 ± 0.7 Å (Table
10.1). These data suggest that spermine binding stabilizes the GluN1 ATD in an open
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changes can be propagated towards the LBDs and pore of the receptor. In the case of zinc
inhibition, we have previously shown that the upper lobes of the ATDs do not undergo any
conformational changes during zinc inhibition or upon binding of the agonists glutamate and
glycine (Sirrieh, MacLean et al. 2013). To probe the upper lobes of the ATDs during spermine
95

Figure 10.3: Spermine binding does not affect the upper lobes of the ATDs. (A)
These curves are the sensitized acceptor emission for receptors labeled at the upper
lobes of the ATDs. The lifetime does not change when spermine is bound. (B) The donor
only lifetimes for the measurements between the upper lobes of the ATDs are shown. In
all panels, the black curve is from the apo receptor and the blue curve is from the
spermine-bound receptor.
potentiation, measurements were next made by co-expressing the GluN1*C22 construct with
GluN2B*H30 and labeling the receptor with terbium chelate and Ni(NTA)2Cy3. These constructs
allowed for the specific introduction of the donor fluorophore at the upper lobe (N-terminus) of
the GluN1 ATD and the acceptor fluorophore at the upper lobe (N-terminus) of the GluN2B
ATD. As with previous constructs, the potentiation by spermine was near wild-type levels, with
the equilibrium response increased by 1.76 ± 0.08 (n=7) fold (Figure 10.2). The LRET lifetime
for the apo receptor was well represented by a single lifetime of 362 ± 26 µs (Figure 10.3),
corresponding to a distance of 52.1 ± 0.6 Å (Table 10.1). The binding of spermine to the
receptor resulted in no change in the distance, as the lifetime was 311 ± 43 µs (Figure 10.3),
giving a distance of 50.7 ± 1.2 Å (Table 10.1). The upper lobes of the ATDs are not moving
with respect to each other when spermine binds, but spermine opens up both the GluN1 and
GluN2B ATDs. Collectively, these data suggest that spermine binding causes the movement
of the lower lobes of the ATDs.
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To map the movement of the lower lobe of the GluN2B ATD, which is stabilized in an
open conformation when spermine binds, we measured the LRET between the lower lobe of
the GluN2B ATD and the upper lobe of the GluN1 ATD. The GluN1*C22 construct was coexpressed with GluN2B*232 and labeled with terbium chelate and Alexa555. Spermine
potentiation was preserved in this construct, with a 1.65 ± 0.08 (n=9) fold increase in
equilibrium response (Figure 10.4). The sensitized acceptor lifetime of the apo receptor was
228 ± 16 µs (Figure 10.4), a distance of 47.6 ± 0.6 Å (Table 10.1). The lifetime decreased to
161 ± 14 µs (Figure 10.4) when the receptor was bound by spermine, corresponding to a
distance of 44.6 ± 0.6 Å (Table 10.1).

Figure 10.4: The lower lobe of the GluN2B ATD rotates towards the upper lobe of the
GluN1 ATD. (A) LRET measurements between the lower lobe of the GluN2B ATD
(Cys232) and the upper lobe of the GluN1 ATD show that the lifetime decreases when
spermine is bound. (B) Donor only lifetimes for these constructs are shown. In all panels,
the black curve is from the apo receptor and the blue curve is from the spermine-bound
receptor.
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Ligated State (n)

Donor Only
Lifetime (µs)

Donor-Acceptor
Lifetime (µs)

Distance (Å)

GluN2B Cleft – GluN1* + GluN2B*cleft (Ni(NTA)2Cy3)
Apo (3)

1649 ± 1

252 ± 12

48.8 ± 0.4

Spermine (4)

1659 ± 1

369 ± 34

52.8 ± 0.8

GluN1 Cleft – GluN1*cleft + GluN2B*(Alexa555)
Apo (2)

1740 ± 1

275 ± 4

49.2 ± 0.1

Spermine (2)

1714 ± 1

340 ± 29

51.5 ± 0.7

GluN1-GluN2B Upper Lobes – GluN1*CT + GluN2B*HT(Ni(NTA)2Cy3)
Apo (5)

1724 ± 1

362 ± 26

52.1 ± 0.6

Spermine (2)

1693 ± 1

311 ± 43

50.7 ± 1.2

GluN1 Upper Lobe-GluN2B Lower Lobe – GluN1*CT + GluN2B*232 (Alexa555)
Apo (3)

1706 ± 1

228 ± 16

47.6 ± 0.6

Spermine (3)

1682 ± 1

161 ± 14

44.6 ± 0.6

Table 10.1: Lifetimes and distances from LRET measurements with Spermine. In
parentheses after the ligated state for each construct is the n value. Also, listed next to the
constructs is the acceptor fluorophore used. The donor fluorophore for all measurements
was terbium chelate. The error in the LRET lifetime is the SEM, and the error in the
distances was calculated by propagating the errors in the lifetimes.

10.2 Discussion
Spermine causes the GluN2B cleft to open but the lower lobe of GluN2B seems to be
rotated towards the upper lobe of the GluN1 ATD. These data suggest that although spermine
binding stabilizes an open GluN2B ATD, the lower lobe of the ATD additionally rotates bringing
Cys232 closer to the upper lobe of the GluN1 ATD. Studies attempting to identify the binding
site of spermine identified several acidic residues at the lower lobes of both the GluN1 and
GluN2B ATDs that have an effect on spermine affinity. Residues including Asp170, Glu181,
Glu185, and Glu186 in GluN1 and Glu191, Glu198, Glu200, and Glu201 in GluN2B were
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Figure 10.5: Spermine binding residues. GluN1 subunits are in teal and GluN2B
subunits are in orange. Highlighted in blue on the GluN1/GluN2B ATD dimer are the
proposed spermine binding residues including Asp170, Glu181, Glu185, and Glu186 in
GluN1 and Glu191, Glu198, Glu200, and Glu201 in GluN2B (Mony, Zhu et al. 2011,
Tomitori, Suganami et al. 2012).
identified (residues highlighted in blue in Figure 10.5) (Mony, Zhu et al. 2011, Tomitori,
Suganami et al. 2012). Based on the crystal structure of the full length NMDA receptor
(Karakas and Furukawa 2014, Lee, Lü et al. 2014), it is clear that these residues are too far
apart in the structure to be able to bind spermine. Distances measured between spermine
binding residues highlighted in Figure 10.5 range from 18-23 Å in the crystal structure, but
thiol reactive reagents less than 8 Å in length are able to cross-link the lower lobes of the
GluN1-GluN2B ATDs (Mony, Zhu et al. 2011). In further support of the closer proximity of
these domains at the lower lobes is that cross-linkers less than 8 Å in length can be used to
crosslink the lower lobes of the GluN1-GluN2B ATDs (Mony, Zhu et al. 2011). The crystal
structures were obtained in the presence of the allosteric inhibitors ifenprodil in one case and
Ro25-6981 in the other (Karakas and Furukawa 2014, Lee, Lü et al. 2014). These structures
thus would correspond to an inhibited state of the receptor. Consequently, spermine binding
to these residues should be expected to move the lower lobes of the ATDs closer.
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This work provides insight into the conformational changes occurring upon potentiator
binding to the ATDs of the NMDA receptor. We can conclude that the upper lobes of the ATDs
are stable and do not undergo any large conformational changes on average when spermine
binds (Figure 10.3). However, spermine binding does cause an opening of the ATDs of both
the GluN1 and GluN2B ATDs (Figure 10.1). The measured distances of the GluN1 and
GluN2B ATDs match the distances in the ATDs in the full-length structure (Karakas and
Furukawa 2014, Lee, Lü et al. 2014). The lack of movement of the upper lobes of the ATDs
suggests that the movements taking place are due to movement of the lower lobes of the
ATDs. When looking at the crystal structures of the full length NMDA receptor (Karakas and
Furukawa 2014, Lee, Lü et al. 2014), the residues are too far apart in that, presumably
inhibited, state to bind spermine. For binding to occur, these residues must be brought closer,
requiring a rotation of the lower lobes of the ATDs in order to bridge the distance. We infer
this rotation from the combined opening of the GluN1 and GluN2B ATDs and the movement
of the lower lobe of the GluN2B ATD towards the upper lobe of the GluN1 ATD. Moreover,
these findings are consistent with cross-linking studies that suggested that mobility of the
lower lobes of the ATDs are critical to allosteric modulation (Karakas, Simorowski et al. 2011).
Overall, the data suggest that spermine potentiates the NMDA receptor by stabilizing open
conformations of both the GluN1 and GluN2B ATDs.
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Chapter 11:
Conclusions, Impact, and Future Directions
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11.1 Conclusions
Our data show that the ATDs of NMDA receptors are indeed organized as a dimers of
heterodimers. Further, the data show that the ATDs of NMDA receptors adopt a significantly
more compact arrangement than the ATDs of AMPA and kainate receptors. The upper lobes
of the ATDs do not undergo any large-scale conformational changes upon binding any ligand
(Sirrieh, MacLean et al. 2013). The binding of the agonists and subsequent desensitization
was thought to cause a rupture in the ATDs so that they separated, something that has now
been demonstrated in AMPA receptors (Meyerson, Kumar et al. 2014). However, in our steady
state measurements of ATD organization, the binding of glutamate and glycine and
subsequent desensitization of the receptor yielded no changes in the distances between
subunits, suggesting that NMDA receptors have a unique mechanism of desensitization that
does not result in separation of the ATDs. Further, it can be conjectured that the compact
nature of the ATD layer results in close contacts between the subunits which would be
energetically unfavorable to break. The lack of change in the ATD inter-subunit distances
upon binding of an allosteric modulator corresponds well with a mechanism that involves the
propagation of conformational changes within an ATD to the LBD layer and ultimately the pore
of the receptor to influence the function. In order for this mechanism to work, the receptor
requires an anchor point, which our data suggest is provided by the upper lobes of the ATDs.
The binding of zinc, ifenprodil, or spermine induces conformational changes in the ATDs, but
the upper lobes remain stable.
The GluN2A and GluN2B ATDs have unique inherent conformations, with the more
open GluN2A ATD correlating with a higher Po of the receptor and the more closed GluN2B
ATD corresponding to a lower Po of the receptor. Additionally, we show that the GluN1 ATD
adopts a different conformation depending on the GluN2 subunit with which it is coassembled. Based on these data, we propose that the differences in both GluN1 and GluN2
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ATDs contribute to unique interfaces between the GluN1/GluN2 ATDs that underlie subtype
specific modulators. Furthermore, both the GluN1 and GluN2 ATDs together dictate Po of the
receptor.

Figure 11.1: Comparison of GluN2 Cleft Conformations. Plotted
are the distances measured using the GluN2cleft constructs.
GluN2B is inherently more closed than GluN2A, and the modulators
shift the distances to be more like the other GluN2 subtype.
We found that zinc inhibition of GluN2A receptors occurs by stabilizing a closed
conformation of the GluN2A ATD, inducing a ~4 Å decrease between sites in the upper and
lower lobes (Sirrieh, MacLean et al. 2013). This cleft-closure in the ATD seems to be a
common mechanism of allosteric inhibition, as ifenprodil induces a cleft-closure in the GluN2B
ATD. Conversely, spermine, which potentiates, causes an opening of the GluN2B ATD.
Additionally, the lower lobe of the GluN2 ATD undergoes a rotational movement, independent
of the opening or closing of the domain. The conformation of the ATD can be correlated to the
Po of the receptor. This correlation is not unexpected as correlations have been demonstrated
between the extent of LBD closure and activation of the receptor (Rambhadran, Gonzalez et
al. 2011, Dolino, Cooper et al. 2014). The correlation is similar for receptors composed of
GluN2A or GluN2B receptors, as the slope of the lines is similar (Figure 11.2).
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Figure 11.2: Correlation between ATD conformation and Po. The
points represent a given conformation of the ATD which corresponds to
a certain Po of the receptor. The best fit lines connecting the points have
similar slopes for receptors composed of GluN2A or GluN2B receptors,
suggesting a correlation.
The GluN1 ATD conformation is only affected by the potentiator spermine. Zinc binding
does not influence the overall conformation of the GluN1 ATD. Interestingly, the conformation
of the zinc-bound GluN2A ATD (i.e. low Popen) is similar to the apo GluN2B ATD (48.8 Å and
low Popen) (Figures 11.1 and 11.2). Further, the state of the spermine-bound GluN2B ATD
(52.4 Å and high Popen) is comparable to that of the apo GluN2A ATD (51.4 Å and high Popen)
(Figures 11.1 and 11.2). Taken together, such correlations explain how zinc and spermine
inhibit and potentiate the receptor, respectively, by influencing the average conformation of
the ATD. An inhibitor closes the ATD cleft, while a potentiator opens the GluN2 ATD cleft. If
zinc binding causes a cleft-closure in the GluN2B ATD as expected, then the inherent
difference in the cleft conformation of GluN2A and GluN2B explains why zinc completely
inhibits GluN1-GluN2B receptors but only partially inhibits GluN1-GluN2A receptors (Erreger
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and Traynelis 2005, Rachline, Perin-Dureau et al. 2005). Our results also suggest why
spermine is unable to potentiate GluN2A containing receptors as the resting GluN2A ATD is
already an open conformation. Further, these data suggest that ifenprodil induces smaller
conformational changes because the GluN2B ATD is inherently in a more closed
conformation. To inhibit GluN2B requires less of a conformational change; both GluN1 and
GluN2B are more closed.

11.2 Impact
The studies discussed here provide insight into the structural mechanism of allosteric
modulation. Our data support the mechanism whereby an open ATD conformation results in
a potentiated receptor and a closed ATD results in an inhibited receptor. These studies identify
how a receptor would be manipulated by a drug that seeks to modulate the receptor in a
subtype dependent fashion. The hope is that a subtype specific modulator would allow for
normal, basal synaptic transmission, but still inhibit or potentiate the receptor as needed in a
disease state. Our data have identified the GluN1-GluN2 ATD interface as a unique site on
the receptor that could be used to develop subtype specific modulators. Additionally, the LRET
technique combined with the constructs developed for these studies are great tools to
potentially help characterize new drugs.

11.3 Future directions
The mechanism of propagation of conformational changes at the ATDs to the gating
machinery remains very poorly understood. Stabilizing the LBD interface yields receptors that
are not as greatly inhibited by zinc, suggesting that zinc inhibition proceeds by destabilizing
the dimer interface at the LBD. However, is the conformational change propagated through
the ATD-LBD linker or are new contacts formed between the bottom of the ATD and the top
of the LBD? This question is especially pertinent as there is cooperativity between the LBD
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and ATD. These two domains are linked on a deeper level than that related simply to channel
activation.
To attempt to address this question, we inserted a glycine residue into the linker
between the ATD and LBD. This technique was used in the S2-M3 linker and the insertion
was able to decouple conformational changes at the LBD from the pore of the receptor and
demonstrated that tension in the S2-M3 linker was required for gating of the receptor (Kazi,
Dai et al. 2014). If the conformational changes at the ATD were similarly propagated to the
LBD through tension in the linkers, we would similarly expect a decreased extent of inhibition.
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Figure 11.3: Effect of Glycine Insertions in the ATD-LBD Linker. (A) A
representative trace of zinc inhibition of a GluN1-GluN2A receptor. (B) A
representative trace showing the rate of MK-801 binding in the presence
and absences of zinc. (C) Summary data from recordings from mutants
with a single glycine inserted in the GluN1 (blue) or GluN2A (green) ATDLBD linker. (D) The rates of MK-801 binding in the presence and absence
of zinc for wild type receptors and the mutants with glycines inserted in the
ATD-LBD linkers. Electrophysiology performed by Dr. David MacLean.
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A single glycine inserted in the ATD-LBD linker of either the GluN1 or the GluN2A subunit
resulted in modest reductions in the extent of zinc inhibition (Figure 11.3). However, to
determine that only zinc inhibition and not the inherent function of the receptor was altered by
this mutation, the Po of the mutant channel needed to be determined. As a way of estimating
the Po of these mutants, the rate of binding of the open channel blocker MK-801 was used as
a marker of activation. In the wild type receptor, MK-801 binding was markedly slower in the
presence of zinc, as expected because zinc inhibition proceeds by reducing Po. The GluN2A
mutant followed this trend, and had similar rates of MK-801 binding to the wild type receptor.
However, the GluN1 mutant was quite strange because, despite normal MK-801 binding in
the absence of zinc, it had identical MK-801 binding in the presence of zinc (Figure 11.3),
suggesting that some compensatory effect of the mutation had taken place. The reduction in
zinc inhibition was insufficient to explain the increased rate of MK-801 binding in the presence
of zinc. These results suggest that it is not simply tension in the linker that connects
conformational changes in the ATD to the LBD. However, they do suggest that the GluN1
linker has an interesting role in channel gating that remains uncharacterized. The recent fulllength structures revealed that there are extensive contacts between the ATD and LBD layers
in the NMDA receptor (Karakas and Furukawa 2014, Lee, Lü et al. 2014) (Figure 11.4).
Probing the interfaces between these domains for changes accompanying modulation may
also provide insight into how allosteric modulators affect the LBDs and ultimately the pore of
the receptor. The linkers are one of the more underrated sections of the receptor. Due to their
modification and the deletion of residues to generate a stable structure for crystallography,
we do not have a clear picture of the structure adopted by the linkers. How the linkers, despite
their relatively short length, manage the crossover between subunits is an interesting
structural question that may be difficult to answer with crystallography due to their dynamic
nature.
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The question of proton inhibition in light of the conformational changes characterized
here is a very interesting question. The binding of zinc, ifenprodil, and spermine do induce
conformational changes. How do those conformational changes relate to proton inhibition?
Attempts to answer these questions were not possible to address with LRET because
repeating the measurements at different pHs did not induce significant changes in the LRET

Figure 11.4: ATD-LBD contacts. The crystal structure
highlighting the contacts between the ATD and LBD layers is
shown. The GluN2B subunit is in blue and the GluN1 subunit
is in green. The GluN2B ATD is positioned such that it can
make direct contacts with both the GluN1 and GluN2B LBDs.
lifetime, suggesting that either the conformation is not affected by pH or that the LRET
technique is not sensitive enough to detect small changes in distributions.
Finally, more work is needed on triheteromeric receptors to characterize the kinetics
of their activation and to better understand how they are modulated. In the central nervous
system, NMDA receptors are believed to assemble as triheteromeric receptors; in
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hippocampal neurons that express both GluN2A and GluN2B receptors, close to two-thirds of
receptors are composed of two GluN1 subunits, one GluN2A subunit, and one GluN2B subunit
(Tovar, McGinley et al. 2013). In studying the kinetics of these receptors in neurons,
triheteromeric receptors were found to have intermediate decay kinetics between GluN1/2A
and GluN1/2B diheteromeric receptors (Tovar, McGinley et al. 2013). To address the question
of allosteric modulation in triheteromeric receptors, a set of mutations that modify an individual
subunit’s response to magnesium, zinc, or glutamate were introduced (Hatton and Paoletti
2005). The results of this study show that triheteromeric receptors have intermediate inhibition
by ifenprodil and zinc compared to their diheteromeric counterparts, although they retain
roughly the same affinity as the diheteromeric receptor (Hatton and Paoletti 2005). Receptors
with only one zinc binding site retain nanomolar zinc affinity, but are inhibited to a much lesser
degree (Hatton and Paoletti 2005). Another recent effort to study triheteromeric receptors
employed ER retention signals in the CTD that would be suppressed by the assembly of a
triheteromeric receptor (Hansen, Ogden et al. 2014). This study similarly found that
triheteromeric GluN1/GluN2A/GluN2B receptors retain high affinity zinc binding, but are
inhibited only to the same extent as GluN1/GluN2A wild type receptors, which are
incompletely inhibited by saturating zinc (Hansen, Ogden et al. 2014). These receptors are
also inhibited by ifenprodil, but to a lesser degree than GluN1/GluN2B receptors, and they
had a lower affinity to ifenprodil (Hansen, Ogden et al. 2014). The Paoletti group also took
advantage of this technique to express triheteromeric receptors and found that these
GluN1/GluN2A/GluN2B receptors had intermediate deactivation kinetics, agonist EC50s, and
zinc, ifenprodil, and proton IC50s compared to the diheteromeric species but were only mildly
potentiated by spermine (Stroebel, Carvalho et al. 2014). The extent of inhibition was also
intermediate (Stroebel, Carvalho et al. 2014).

109

The techniques that allow for the isolation of triheteromeric receptors is still a challenge
even with the development of the C-terminal retention signals. Diheteromeric receptors
expressed using the retention signals have an abnormally low Po (Hansen, Ogden et al.
2014), so, though they reflect great progress, they are still not an accurate in vitro
representation of these receptors. As the technologies develop, studying triheteromeric
receptors, including receptors that have GluN3 subunits, will provide the greatest insight into
the way NMDA receptors are involved in neural network formation physiologically and really
help us understand how synaptic transmissions are fine-tuned, because triheteromeric
receptors are very prevalent in the central nervous system. Advances in our ability to
recombinantly express triheteromeric receptors will definitely help the field to do the necessary
experiments.
NMDA receptors are well-balanced structures; binding of an agonist or modulator adds
energy to the system and tips the balance in a direction that alters the function of the receptor.
Multiple ligands binding simultaneously modulate each other’s binding to the receptor
(cooperativity between binding sites) in addition to their functional effect. Simple features such
as electrostatics also contribute to this balance, and the links between all the binding sites
and functions of this intricate machine are still works in progress. Our work contributes to the
understanding of how modulators which bind to the ATDs affect the structure and cause a
functional effect.
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Appendix: Definitions of Terms Describing Ion Channel Properties
glutamate
Steady state
current
amplitude
Peak
current
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Deactivation
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Time
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Appendix Figure 1: Anatomy of an electrophysiological recording
from an NMDA receptor. One can see the rapid rise time, little
desensitization, and rapid deactivation. By convention, only glutamate
is listed because the cell is kept in the continual presence of glycine,
as the receptors are thought to be at synapses.
 allosteric modulation: binding of modulator to a site on the receptor other than the agonistbinding site (non-competitive) results in a modification of the function of the receptor.
 burst: period of activity in single-channel recordings during continuous application of the
agonist
 conductance: charge per unit time passed through the pore of an ion channel. There can
be one conductance state or several conductance states, where the smaller conductance
states are typically called subconductance states. The conductance is an inherent property
of the receptor/channel in question.
 cooperativity: The binding of a ligand to one site on a protein changes the affinity for
another ligand which binds at a different site on the receptor. Cooperativity is one
mechanism by which allosteric modulation may proceed.
 deactivation: the closing of the channel due to removal of the agonist.
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 desensitization: the state in which a channel is in the closed conformation despite being
bound by agonist, during the continual application of agonist. The desensitized state has a
higher affinity for the agonist than the apo state.
 extent of desensitization: can be defined as the ratio of steady state current to peak
current.
 holding potential: the membrane potential at which a patch or cell is maintained during
electrophysiological recording.
 mean closed time: The length of time within a burst during single-channel recordings when
the channel is closed.
 mean open time: the length of time within a burst during single-channel recordings when
the channel is open
 open probability (Po): The chance that the channel will be open at any given time. The Po
increases significantly upon application of the agonist. The open probability is typically
expressed on a scale from 0 to 1, with 1 being 100% chance of activation.
 peak current amplitude: the amplitude of current passed through the ion channels in a
patch or whole-cell configuration immediately upon activating the receptor with agonist. This
current is expressed in nAmps or pAmps.
 rise time: the time it takes for a channel to go from 10-90% current upon application of the
agonist. The range of 10-90% is somewhat arbitrary, and is sometimes replaced with time
from 20-80%.
 steady state current amplitude: The current that passes through the channels in a patch
or whole-cell configuration during continuous application of the agonist after the channel has
equilibrated between open, closed, and desensitized states.
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